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1. Introduction 
1.1 Colorectal Cancer  
Colorectal carcinoma (CRC) are malignant neoplasms arising from the caudal midgut and 
the hindgut. They exhibit local invasive growth, lymphogeneous metastatic spread to regional 
lymph nodes and hematogeneous spread to distant organs, most notably liver and lungs. 
The majority of CRC are caused by acquired DNA-mutations and epigenetic alterations 
(McCoy and Weinberg 1983, The Cancer Genome Atlas Network 2012), while a fraction of 
colorectal cancers are caused by hereditary susceptibilities (Dietmaier et al. 2000, Umar et 
al. 2004). As adenocarcinoma arising from the epithelial lining of the gut is the most common 
tissue of origin, CRC is often regarded synonymic for adenocarcinoma. However, any tissue 
belonging to the large intestine may undergo malignant transformation. Given their 
differences in anatomy and clinical treatment, colon and rectal cancer must clearly be 
defined. In spite of their distinct properties, their underlying biology seems comparable, as it 
is indicated by the emerging comprehensive molecular landscape of colorectal cancer (The 
Cancer Genome Atlas Network 2012). The histopathology of biopsies and surgical resections 
of colorectal cancer, including a detailed investigation of the lymph nodes for metastasis, is 
essential for diagnosis and the staging of CRC, as well as clinical decision-making and high-
quality medical care (Virchow 1898, Nathan et al. 2011). 
1.1.1 The Epidemiology of Colorectal Cancer 
In 2008, 1.235 million new cases of CRC occurred worldwide, making it the third most 
common type of cancer in the world after lung cancer and breast cancer (data: IARC, 
Globocan Fast Stats 2008). It is also the second most frequent cause of cancer-related death 
in Europe (Ferlay et al. 2007), including Germany. In Germany, 35,360 men and 30,040 
women suffered from CRC in 2008 and forecasts suggested these numbers would rise to 
38,300 men and 31,100 women in 2012. Like most solid tumors, CRC predominantly affects 
the elderly: In Germany, over 50% of all patients diagnosed with CRC are 70 years or older 
and only 10% are diagnosed before the age of 55. The mortality rate, on the other hand, has 
declined by more than 20% since 1999 for both men and women, and was 0.24 for men and 
0.14 for women in 2008 (data: "Krebs in Deutschland", chapter "Darm C18-21"). In the U.S., 
CRC is the third most common type of cancer after lung cancer and prostate cancer (Siegel 
et al. 2013). Incidence rates increase with age, the median age at diagnosis for CRC being 
69 (data: SEER Cancer Statistics Review 1975-2009). Mortality rates in the U.S. have been 
decreasing since 1950 in women and since 1980 in men. In contrast to Germany, incidence 
rates have shown slight decreases in the U.S. since 1998, 3% per year for men and 2.3% 
per year for women (Kohler et al. 2011). Decreasing incidence and mortality rates in the U.S. 
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are accompanied by an increase in the 5-year relative survival rate for CRC, which increased 
for men and women from 51.7% in 1981-1983 to 68.1% in 2002-2008 (data: SEER Cancer 
Statistics Review 1975-2009). 
1.1.2 Risk Factors 
The known risk factors for CRC can be subdivided into modifiable and nonmodifiable risk 
factors. Nonmodifiable risk factors are sex, genetic susceptibility as represented by a 
personal or family history of adenomatous polyps or colorectal cancer and chronic 
inflammatory bowel disease. Incidence and mortality rates are about 35 to 40% higher for 
men than for women (American Cancer Society 2011). Patients who have first degree 
relatives with a colorectal carcinoma run a risk two to three times as high developing CRC 
themselves (Schmiegel et al. 2008). Patients with inflammatory bowel disease, most notably 
colitis ulcerosa, have an increased risk of cancer of the colon and the rectum, respective to 
the duration and extent of colitis. Patients with pancolitis, for example, have a relative risk of 
14.8 of developing CRC compared to the general population (Ekbom et al. 1990). The 
modifiable risk factors encompass life-style habits, including the so-called 'Western-type' diet 
with a high consumption of red or processed meat, highly caloric food and physical inactivity 
(Bosman et al. 2010). While incidence rates have stabilized or only slightly increased in 
economically developed countries such as Western Europe or Australia, Center et al. 
observed a continuing increase in CRC incidence rates in newly-industrialized countries such 
as Slovakia or Poland, reflecting the association of CRC to a recently-adopted western 
lifestyle (Center et al. 2009). The EPIC study investigated dietary habits of 478,040 men and 
women from 10 different European countries over a 6-year period and observed a linear 
increase in the hazard ratio by 1.49 for colon cancer and by 1.65 for rectal cancer per 100g 
consumed red and processed meat per day (Norat et al. 2005). Based on such findings, both 
the current German guidelines on CRC and the 2012 guidelines on Nutrition and Physical 
Activity for Cancer Prevention from the American Cancer Society recommend limiting the 
consumption of red and processed meat and alcohol, while regular consumption of high-fiber 
foods, fruits and vegetables is encouraged (Schmiegel et al. 2008, Kushi et al. 2012). Since 
male smokers have an estimated relative risk of 1.32 and female smokers an estimated 
relative risk of 1.42 of developing CRC (Chao et al. 2000), both guidelines also advise not 
smoking (Schmiegel et al. 2008, Kushi et al. 2012). Protective factors include a fiber-rich diet, 
physical activity and maintaining a healthy weight. A recent Danish study concluded that 
about 23% of CRC cases might be avoided by adhering to a healthy lifestyle (Kirkegaard et 
al. 2010).  
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1.1.3 Pathogenesis 
Colorectal cancer is a genetic disease, approximately 90% of all cases resulting from 
sporadic DNA mutations (Riede et al. 2004). Among all cancers, CRC is possibly best 
understood on the molecular level. The first known cellular proto-oncogene, k-ras, was 
initially isolated from colon cancers (McCoy and Weinberg 1983), and the concept of step-
wise carcinogenesis was derived from observations in CRC (Fearon and Vogelstein 1990). 
Malignant neoplasms have defined properties that distinguish them from normal tissues. 
These 'hallmarks' (Hanahan and Weinberg 2000 and 2011) are mediated by changes in 
gene expression. Each hallmark may be caused by several different kinds of alterations 
affecting different genes. CRC might be considered the archetypical model for the step-wise 
acquisition of these hallmarks: a common first step is a protein-coding mutation in the 
Adenomatosis Polyposis Coli (APC) gene. The resulting loss of APC function causes 
stabilization of the protein beta-catenin, which acts as a transcription factor together with 
TCF/LEF proteins to activate a set of genes involved in cell growth and self-renewal, 
including cell-cycle protein Cyclin D1 and proto-oncogene c-Myc (Kumar et al. 2010). 
Subsequent mutations may include activation of proto-oncogene k-ras, which promotes PI3 
kinase-related cell growth and possibly cellular plasticity (Ischenko et al. 2013), loss of tumor 
suppressor DCC and finally loss of function of the central tumor suppressor TP53. The 
acquisition of activating and silencing mutations is thought to underlie the adenoma-
carcinoma-sequence, the clinically observable formation of CRC: initial events such as loss 
of APC cause formation of adenomatous polyps by mediating self-sustained growth. Within 
years, these benign precursor lesions may eventually undergo malignant transformation and 
become invasive carcinomas, e.g. by TP53-loss. On the molecular level, two major 
phenotypes of CRC adenocarcinomas can be distinguished: tumors with chromosomal 
instability (CI) and tumors with DNA-mismatch-repair defects, indicated by the presence of 
microsatellite instability (MSI). The 'classical' adenoma-carcinoma sequence is usually 
accompanied by CI causing alterations in the copy number and structure of chromosomes 
(Markowitz and Bertagnolli 2009). MSI results from inherited or acquired mutations in DNA 
mismatch-repair genes and underlies about 15% of all CRC (Umar et al. 2004), and about 
90% of the cases involving patients with hereditary nonpolyposis colorectal cancer (Bocker et 
al. 1997), the most common type of hereditary CRC-disposition.  
1.1.4 Genetic Factors 
In about 5% of all cases, CRC is caused by a genetic syndrome. These syndromes may 
manifest themselves as colonic polyposis as in Familial Adenomatous Polyposis caused by 
hereditary APC mutation and in Peutz- Jeghers- Syndrome. Other syndromes, such as the 
hereditary nonpolyposis colorectal cancer syndrome (HNPCC), do not feature increased 
numbers of polyps. HNPCC, or Lynch syndrome, is the most common genetic syndrome 
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responsible for CRC, causing 2 to 4% of all CRC cases (Jasperson et al. 2010) and is 
characterized by a deficiency in DNA-mismatch-repair, autosomal dominant inheritance and 
neoplastic lesions that occur in young adults. Identification of HNPCC patients is facilitated 
by reference listings of diagnostic criteria, most notably the Amsterdam criteria and the 
revised Bethesda criteria (Herold 2011). Patients with HNPCC have a risk of up to 80% of 
developing CRC throughout their lifetime and have increased rates of kidney, ovary and skin 
cancer. Thus, in such cases, an annual colonoscopy is recommended as early as the age of 
25 (Schmiegel et al. 2008). On the genomic level, the mismatch-repair-deficiency is indicated 
by length-changes of small repetitive DNA-sequences, so-called microsatellites. 
Microsatellite instability is defined as an alteration of the length of these microsatellites and 
occurs in about 90% of patients with HNPCC and in about 15 to 30% of all patients with 
sporadic CRC (Bocker et al. 1997). A panel of five defined microsatellite sequences in the 
tumor should be tested for mutations in patients suspected of having HNPCC. Depending on 
whether 2, 1 or none of the five microsatellite sequences of the tumor DNA have been 
mutated, MSI can be further classified as MSI-high, MSI-low or MSI-stable (Umar et al. 
2004). A practical approach to screening for MSI is the detection of the most commonly 
involved mismatch-repair enzymes by immunhistochemistry: MSH2, MLH1, MSH6 and PMS2 
on tissue sections of a biopsy of a surgical specimen. Loss of either of these proteins is 
highly predictable for HNPCC or acquired MSI (Jasperson et al. 2010).  
1.1.5 The Classification and Metastatic Spread of CRC 
Colorectal carcinoma show both lymphatic and hematogenous metastatic dissemination. The 
first targets of lymphatic metastases are regional lymph nodes of the section of the bowl the 
tumor is located in (Riede et al. 2004). Organotypic hematogenous metastatic spread 
depends on the location of the tumor. Blood from the rectum is drained by the hemorrhoidal 
plexus, which forms an anastomosis between the portal system and the systemic circulation. 
The lower part of the rectum and the anal canal are drained by the middle rectal vein, which 
connects with the inferior vena cava via the internal iliac vein and by the lower rectal vein, 
which connects to the inferior vena cava via the internal pudendal vein and internal iliac vein 
(Aumüller et al. 2007). Thus, tumors of the upper and middle rectum cause liver metastases 
in over 50% of patients, and tumors of the lower rectum may cause early lung metastases 
(Herold 2011). The systemic venous drainage of the lower rectum is pharmacologically 
employed by suppositories, as hepatic first-pass metabolism is circumvented. Because of 
this anastomosis between hemorrhoidal plexus and portal system, portal hypertension 
especially in liver cirrhosis, may cause rectal varices (Aumüller et al. 2007). 
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Tumor Stage according to the UICC: 
T-Tumor                                                                       
T1- Tumor invades submucosa 
T2- Tumor invades muscularis propria 
T3- Tumor invades the muscularis propria in  
      subserosa or nonperitonealized pericolic or  
      perirectal tissue  
T4-Tumor invades adjacent organs or other 
     structures and/or perforates visceral peritoneum 
 T4a- Tumor perforates visceral peritoneum 
T4b- Tumor invades other organs or 
structures 
 
N-Regional Lymph Nodes 
N1- Metastasis in 1 to 3 regional lymph nodes 
 N1a- Metastasis in 1 regional lymph node 
 N1b- Metastasis in 2 to 3 regional lymph  
nodes 
N1c- Tumor deposits or satellites in the 
fatty tissue of the subserosa or the 
nonperitonealized pericolic or perirectal 
fatty tissue without distant metastasis  
N2- Metastasis to 4 or more regional lymph nodes 
 N2a- Metastasis to 4 to 6 regional lymph  
nodes 




M0- No distant metastasis 
M1- Distant metastasis 
 M1a- Metastasis confined to one organ or  
site 
 (liver, lung, ovaries, non-regional lymph  
 nodes) 
M1b- Metastases in more than 1 organ or  




(Wittekind and Meyer 2010, p.96-97)
Stage 0 Tis N0 M0 
Stage I T1, T2 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T4a N0 M0 
Stage IIC T4b N0 M0 
Stage III Every T N1, N2 M0 
Stage IIIA T1, T2 N1a M0 
 T1 N2a M0 
Stage IIIB T3, T4a N1 M0 
 T2, T3 N2a M0 
 T1, T2 N2b M0 
Stage IIIC T4a N2a M0 
 T3, T4b N2b M0 
 T4b N1, N2 M0 
Stage IVA Every T Every N M1a 
Stage IVB Every T Every N M1b 
Table 1.1 
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1.1.6 The Staging of Isolated Tumor Cells and Micrometastases 
Micrometastases are defined as infiltrated lymph nodes with a diameter of 0.2 to 2mm, while 
isolated tumor cells are defined as single cells or cells cluster with a diameter no larger than 
0.2mm. The distinction between macrometastasis, micrometastasis and isolated tumor cells 
should be observed and a distinction in the classification of nodal status of micrometastasis 
and isolated tumor cells should be made as well: 
 
Status Classification 
Both macro- and micrometastases are found pN1 or pN2 
Solely micrometastasis is found The supplement ‘mi’ can be used.  
E.g.: pN1 (mi) or pN2 (mi) 
Isolated tumor cells are detected The supplement ‘i+’ or ‘mol+’ can be used, 
depending on the method the isolated tumor cells 
were detected with: 
 
-pN0 (i+) if the isolated tumor cells were detected 
using morphologic methods, such as H&E 
staining 
-pN0 (mol+) if the isolated tumor cells were 





Table 1.2 The Staging of Isolated Tumor Cells and Micrometastases 
The usage of the abovementioned supplements, though optional, is nevertheless 
recommended (Wittekind and Meyer  2010). 
 
1.1.7 Symptoms and Screening 
Colorectal carcinoma is anatomically unevenly distributed. Two thirds of CRC are located in 
the colon, 30% can be found in the rectum, which forms 10% of the length of the large 
intestine (data: "Krebs in Deutschland", chapter "Darm C18-21"). Patients with colorectal 
cancer rarely show early symptoms, and the disease can remain undetected for a long time. 
Once tumor symptoms occur, patients may present with rectal bleeding due to the ulceration 
of the tumor, which can also cause anemia and patients feeling fatigued. Obstructive growth 
of the tumor may result in pain or changes in bowl habits, such as constipation or diarrhea. 
As 10% of rectal tumors can be palpated (Herold 2011), gold standard in screening and 
diagnosis is performing a digital rectal examination, followed by a colonoscopy and possibly 
polypectomy, which have proven to reduce incidence rates up to 90% (Winawer et al. 1993). 
According to current treatment guidelines, colonoscopy is recommended every ten years 
(Schmiegel et al. 2008) since studies have shown that it takes 10-15 years from initial 
formation of a polyp to invasive carcinoma (Kelloff et al. 2004). Alternately, an annual fecal 
blood test can be used as a screening method. The test relies on the detection of occult 
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blood and is less sensitive compared to colonoscopy but has also proven to significantly 
decrease the incidence of colorectal carcinoma (Mandel et al. 2000).  
1.2 The Therapy of CRC 
1.2.1 The Definition of CRC 
The colon is approximately 1.5 meters in length, subdivided into the ascending, the 
transverse, the descending and finally the sigmoid colon. Of these four parts, only the 
transverse and the sigmoid colon are intraperitoneal, while the ascending and descending 
colon are attached to the rear wall of the abdominal cavity and located secondarily 
retroperitoneal. The peritoneal covering of the sigmoid colon can expand to the front of the 
upper rectum, causing it to be secondarily retroperitoneal or even intraperitoneal, depending 
on the extent of the peritoneal covering. The rectal ampulla and anal canal are located in the 
small pelvis below the abdominal cavity (Martini et al. 2006). In Germany, the gold standard 
for distinguishing between colonic and rectal cancer is the distance from the anocutaneous 
line to the distal edge of the tumor measured by rigid rectoscopy. Tumors more than 16cm 
from the anocutaneous line are considered colonic whereas tumors 16cm or less are 
considered rectal tumors. Tumors of the rectum are further subdivided into tumors of the 
upper, middle or lower part of the rectum according to the distance of the tumors from the 
anocutaneous line (12 to 16cm, 6 to 12cm and less than 6cm respectively) (Schmiegel et al. 
2008). These compartments differ in abundance of lymph nodes and of metastatic spread 
(Sprenger et al. 2010, Sprenger et al. 2013b). American guidelines, on the other hand, define 
rectal cancer as tumors located 12cm or closer to the anocutaneous line. The American 
definition is based on the local recurrence rates of tumors located 12cm or more from the 
anal verge, which are similar to the rates of colon tumors (Nelson et al. 2001). 
1.2.2 The Therapy of Rectal Cancer 
In the treatment of rectal cancer, all three modalities of oncological treatment are employed: 
surgery, radiation and chemotherapy. Decisions regarding therapy are based on rectoscopy 
for tumor localization and biopsy, on endosonography to determine the depth of tumor 
penetration and possibly on MRI to establish the distance of the tumor from the mesorectum 
(Schmiegel et al. 2008). Surgical treatment is essential for the patient's prognosis and 
depending on the size and the location of the tumor within the rectum, different surgical 
procedures may be used. Each surgical approach aims at complete tumor removal (R0) by 
removing of the tumor using the no-touch-technique and taking into consideration 
recommended safety margins for surgical resection. To ensure an optimal outcome and low 
local recurrence rates, surgical treatment includes resection of the mesorectum and the 
removal of the mesorectal fatty tissue as well as adjacent lymphatic vessels and lymph 
nodes. Mesorectal excision can be performed as Partial or Total Mesorectal Excision (PME, 
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TME) and the GAST-05 study is investigating possible benefits of applying PME instead of 
TME in tumors located in the upper part of the rectum (Hofheinz et al 2012b).  For resection 
of tumors located in the sigmoid-rectal junction or the proximal rectum, treatment guidelines 
recommend anterior resection, which includes resection of the upper part of the rectum 
carrying the tumor as well as PME. This procedure allows preservation of continence by 
establishing an anastomosis between the descending colon and the remaining lower part of 
the rectum. To further improve the patient's continence, prior to establishing the 
anastomosis, a J-shaped pouch of the distal part of the descending colon can be formed. If 
the tumor is located in the central part of the rectum, the entire rectum is removed, resulting 
in a so-called low anterior resection including TME. Resection of tumors located in the lower 
part of the rectum either requires low anterior resection and TME or abdominoperineal 
resection and TME. Abdominoperineal resection includes removal of the entire rectum, 
closing the perineum and forming a sigmoidostomy or descendostomy (Schmiegel et al. 
2008, Siewert et Stein 2012). Besides location and size of the tumor, one of the most 
important factors affecting treatment decisions is the patient’s lymph node status, determined 
after surgical resection, pathological grossing and histopathological examination. The 
presence of lymph node metastases strongly influences tumor stage (table 1.1). Whereas 
perioperative therapy is not recommended for stage I tumors, the standard therapeutic 
approach for colorectal cancer stage II and stage III is preoperative neoadjuvant 
radiochemotherapy (RCT) followed by surgical resection and postoperative chemotherapy 
(Hofheinz et al. 2012b). This procedure was established by the CAO/ARO/AIO-94 study: 
Administering RCT neoadjuvantly instead of postoperatively caused a significant reduction in 
local recurrence rates (Sauer et al. 2004). The effect was recently confirmed by 11-year 
follow-up data (Sauer et al. 2012). Both neoadjuvant and adjuvant chemotherapy rely on 
fluorouracil (5-FU) and folic acid (Schmiegel et al. 2008). Ongoing studies focus on adding 
additional chemotherapeutic agents: the CAO/ARO/AIO-04-trial investigates a regimen 
supplemented by Oxaliplatin. Early data indicate an increased pathological complete 
response of 17% compared to 13% by treatment with 5-FU, folic acid and radiation (Rödel et 
al. 2012). Hofheinz et al. compared the usage of intravenous 5-FU with orally available 
prodrug Capecitabine in the neoadjuvant and adjuvant treatment of locally advanced rectal 
cancer, and observed an increased 5-year overall survival (76% vs 67%) and significantly 
fewer distant metastases (19% vs 28%) (Hofheinz et al. 2012a). Radiotherapy is most 
frequently applied in 25 to 28 fractions with a dose of 45 to 50.4 Gy, followed by surgery after 
4 to 6 weeks (Schmiegel et al. 2008). The currently planned CAO/ARO/AIO-12 study will 
investigate if a longer interval after irradiation might increase pathological complete response 
(data: German Rectal Cancer Study Group, 9th newsletter, February 2013). Despite the 
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progress in local therapy, however, distant metastasis occurs with an unchanged rate in 
about 30% of CRC patients 10 years after resection (Sauer et al. 2012).  
1.2.3 The Therapy of Colon Cancer 
The treatment of colon cancer is based on surgery and chemotherapy as radiotherapy is not 
applicable. The extent of the surgical removal of the bowl depends on the lymph drainage 
area the tumor is located in and the adjacent blood vessels. The tumor is removed using the 
so-called no-touch technique (Müller 2011), and adjuvant chemotherapy may be 
supplemented. The application of adjuvant chemotherapy depends on the patient’s risk for 
local and distant recurrent disease and is usually only indicated if lymph node metastases 
are present (Schmiegel et al. 2008). For stage II patients the benefit of adjuvant 
chemotherapy is still questionable and several studies advise against it (Benson et al. 2004). 
Stage III colon cancer patients, on the other hand, have proven to benefit from adjuvant 
chemotherapy (Gill et al. 2004). Commonly used treatment regimens for adjuvant 
chemotherapy are based on combinations of folinic acid, 5-FU and oxaliplatin (FOLFOX), or 
folinic acid, 5-FU and irinotecan (FOLFIRI) (Schmiegel et al. 2008).  
1.2.4 The Therapy of Patients with MSI 
According to Umar et al., MSI is found in about 15% of all colorectal cancers (Umar et al. 
2004), both in patients with HNPCC and sporadic CRC. However, the decision on therapy is 
currently solely based on tumor stage, while MSI status is not taken into consideration. Jover 
et al. point out that patients with MMR-proficient stage II or III CRC show an improvement in 
overall and disease-free survival of about 20% after being treated with adjuvant 
chemotherapy, whereas this increase in survival could not be found in patients with MMR-
deficient tumors (Jover et al. 2009). Patients with MMR-deficient tumors stages II and III, on 
the other hand, were found to have a better clinical outcome than patients with MMR-
proficient tumors, which has led Lanza et al. to recommend the immunhistochemical analysis 
of MLH1/MSH2 expression as a faster and more economic prognostic marker (Lanza et al. 
2010). Treatment of MMR-deficient colon tumor cells with nonsteroidal anti-inflammatory 
drugs such as aspirin has led to a reduction in the MSI-phenotype (Rüschoff et al.1998), 
suggesting that aspirin might be a possible chemopreventive for patients with MMR-deficient 
tumors (Mc Ilhatten et al. 2007). However, current treatment guidelines on CRC do not 
recommend regular use of aspirin as primary prophylaxis (Schmiegel et al. 2008).  
1.2.5 Possible Biomarkers for the Treatment and Prognosis of CRC  
Since neoadjuvant RCT in combination with standardized surgical tumor removal has led to a 
significant reduction in local recurrence rates, it is currently considered standard for 
treatment of CRC in Germany. The grading of tumor regression was first introduced by 
Dworak et al. (Dworak et al. 1997) and reflects response to RCT. However, response rates 
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vary significantly, which raises the question of how to adequately predict a patient’s response 
to therapy. Accurate prediction would allow for the selection of appropriate treatment 
regimens for patients and therefore optimize multimodal treatment of CRC. Besides 
prediction, forecasting the course of disease, prognosis, is of great importance. Among the 
most important prognostic markers for CRC patients is nodal status as survival rates drop 
from 88.3% in node-negative to 69.1% in node-positive rectal cancer patients (Kanemitsu et 
al. 2012). The nodal status also determines whether adjuvant chemotherapy is applicable as 
it is only indicated for stage III patients (Schmiegel et al. 2008). K-ras mutation status is an 
example of a biomarker that is both prognostic and predictive as it indicates a patient’s 
prognosis and eligibility for treatment with anti-EGFR-therapy. Unlike patients with a k-ras 
mutation, patients with a tumor wild-type for k-ras show better chances of survival and 
benefit from treatment with anti-EGFR-antibody Cetuximab (Van Cutsem et al. 2011). 
Currently, both new prognostic and predictive markers are being investigated. Survivin, for 
example, is able to inhibit the activation of caspase-3 and 7, thus preventing apoptosis (Shin 
et al. 2001), and is regarded as a possible new prognostic marker. Low expression of 
survivin in patients with locally advanced rectal cancer leads to better survival rates while 
significantly reducing the risk of distant metastases (Rödel et al. 2002). Sprenger et al. imply 
that the transmembrane glycoprotein CD133 might be both a new prognostic and predictive 
marker as it is believed to make statements about metastasis and survival in rectal cancer 
patients treated with preoperative RCT. Patients with an increased amount of CD133-positive 
cancer cells were thought to demonstrate higher resistance to preoperative RCT as their 
disease-free survival was lower, while also showing higher residual tumor stages and less 
tumor regression (Sprenger et al. 2013a). The Transvalid trials A and B of the German 
Rectal Cancer Study Group aim at further promoting the concept of 'personalized medicine' 
by submitting biomaterial of CRC patients to genomic analyses prior to treatment. By testing 
the validity of prognostic and predictive biomarkers such as survivin, doctors have the 
possibility of distinguishing between a 'low-risk' and a 'high-risk' patient and thus therapy 
regimens can be adapted according to the patient’s risk in local and distant recurrence 
(Grade et al. 2012). 
1.3 Lymph Nodes 
1.3.1 The Definition of Lymph Nodes, Lymph Node Metastasis and Micrometastases 
Lymph nodes are small, usually round or kidney-shaped lymphoid organs, coated with a 
fibrous capsule, parts of which extend into the node, the trabeculae. Lymphoid fluid enters 
the node through afferent lymphatic vessels, passes through a system of sinuses, which 
subdivides the node into compartments, before exiting the node through the efferent 
lymphatic vessel at the hilus. While passing through the node, about 99% of circulating 
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antigens are removed from the lymph, possibly activating antigen-presenting cells and thus 
stimulating an immune response (Welsch 2010, Martini et al. 2006). The human body 
contains up to 700 lymph nodes (Welsch 2010). Many malignant neoplasms are 
accompanied by lymph node metastases, which cause the swelling of the nodes and are 
often the initial clinical symptom of cancer patients (Herold 2011). CRC shows both 
heamatogenous and lymphogenic dissemination and approximately 40% of CRC patients 
develop lymph node metastases (Parsons et al. 2011). Scientists were aware of the 
existence of isolated tumor cells (ITC) as early as the beginning of the 19th century 
(Hermanek et al. 1999), and the American Joint Committee on Cancer first defined isolated 
tumor cells as single cells or a cluster of cells with a diameter of no more than 0.2mm. Cell 
clusters with a diameter of 0.2 to 2mm or an infiltrate of more than 200 non-cohesive cells 
are considered micrometastases (Sirop et al. 2011).  
1.3.2 The Impact of Micrometastases on Prognosis 
Patients with stage II CRC have a five-year relative survival rate of roughly 90%, compared 
to the five-year survival rate of only 69.6% for stage III colorectal cancer patients (SEER 
Cancer Statistics Review 1975-2009). Despite the more favorable prognosis, about 20% of 
stage II CRC patients die from cancer recurrence (Liefers et al. 1998). Some suggest that 
undetected occult metastases are responsible for this relatively high recurrence rate. Thus, 
the role of micrometastases as a potential prognostic factor especially for stage II patients 
becomes increasingly important. Micrometastases can be detected using conventional H&E 
histology, immunohistochemistry (IHC) or reverse transcriptase polymerase chain reaction 
(RT-PCR). By comparing studies that used either IHC or RT-PCR to detect micrometastases, 
Sirop et al showed that the different methods varied in efficiency as the detection rate of 
micrometastases increased from 24.7% after using IHC to 36.6% after using RT-PCR (Sirop 
et al. 2011). The exact relevance of micrometastases for prognosis is still unclear but a 
reverse correlation seems apparent: Bilchik et al. observed a recurrence rate of 22% in CRC 
patients with micrometastases compared to only 6% in patients without micrometastases 
(Bilchik et al. 2010). Märkl et al. evaluated 44 cases with routinely diagnosed 
micrometastases and, with regard to overall survival, found a similar negative outcome for 
patients with micro- and macrometastases. They could not show a prognostic difference 
between the presence of micrometastases or of isolated tumor cells, but they could show a 
strong trend for negative outcome in the presence of isolated tumor cells (Märkl et al. 2013a). 
Sprenger et al., on the other hand, compared disease-free survival rates of patients solely 
with micrometastases to node-negative patients and observed a similar positive outcome in 
both cohorts (76% vs 86%). However, patients in this trial underwent neoadjuvant RCT, 
which probably accounts for the discrepancy of the results compared to Bilchik and Märkl 
and, according to Sprenger et al., this might indicate that the presence of micrometastases 
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reflects a patient’s response to radiation and chemotherapy (Sprenger et al. 2013b). Despite 
these data the concept of micrometastases and their impact on prognosis is not generally 
accepted: In a survey performed by Short et al., 42% of the 602 clinicians questioned about 
the prognostic relevance of micrometastases were unsure and 7% did not believe in it at all. 
Only 15% used IHC on lymph nodes regularly (Short et al. 2012).  
1.3.3 The Importance of Nodal status for Therapy 
The presence of lymph node metastases in patients with CRC is decisive in determining the 
tumor stage: If no lymph node metastases are present, tumor stage depends mainly on the 
depth of tumor infiltration and can be classified as UICC stage 0, I, or IIA-C. As soon as at 
least one regional lymph node is infiltrated, the tumor is classified as UICC stage IIIA-C, 
depending on the number of nodes affected (Wittekind and Meyer 2010). A different tumor 
stage ultimately leads to different approaches in therapy: The decision to apply adjuvant 
chemotherapy requires R0-resection of the tumor and is based on tumor stage, which relies 
on the nodal status. According to treatment guidelines, adjuvant chemotherapy is not 
indicated for stage I colon cancer patients and since studies have not been able to prove 
significant survival benefit for stage II colon cancer patients receiving adjuvant chemotherapy 
(Gill et al. 2004), it is only recommended for patients with high-risk stage II colon cancer, 
such as T4-tumors or patients presenting with tumor perforation (Schmiegel et al. 2008). 
1.3.4 The Importance of Nodal Status for Survival and Prognosis 
Studies have shown that the 5-year disease specific survival after curative resection is 94.1% 
for stage II and 79.1% for stage III colon cancer patients as well as 88.3% for stage II and 
69.1% for stage III rectal cancer patients, demonstrating the impact of nodal status on 
survival (Kanemitsu et al. 2012). O’Connell et al. examined possible factors that have an 
impact on recurrence rates in CRC patients. In their study, 80% of all patients with cancer 
recurrence were stage III colon cancer patients while the remaining 20% with recurrence 
were stage II patients. They also observed that unlike stage III patients, stage II patients 
survived longer after tumor recurrence occurred (O’Connell et al. 2008). This demonstrates 
the impact of nodal status on both survival and prognosis. To ensure adequate staging, the 
UICC recommends that a minimum of 12 lymph nodes in CRC patients should be evaluated 
(Nelson et al. 2001). Controversies remain about the number of lymph nodes that should be 
retrieved and their prognostic value. Several studies have shown that an increased number 
of harvested lymph nodes in CRC patients were correlated with better prognosis, such as 
Kotake et al., who compared survival rates of stage II and III CRC patients on the basis of 
the number of lymph nodes retrieved and show that a larger number of nodes retrieved 
correlated with a decreased risk in death and therefore a better prognosis in both stage II 
and III colorectal cancer patients (Kotake et al. 2012). Although the connection of increased 
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node sampling and better prognosis is widely accepted, the reason for this connection is still 
debatable. The fact is, however, although there is a benchmark on the number of nodes to 
be examined, there is no recommendation or guideline on how to standardize the process of 
finding and harvesting lymph nodes, even though studies have shown different degrees of 
efficiency of pathological methods for lymph node harvest (Denham et al. 2012). 
1.4 The Pathological Workup of Lymph Nodes 
1.4.1 The Pathological Workup of Lymph Nodes 
Studies demonstrate that the percentage of hospitals complying with the recommended 
minimum of harvesting at least 12 lymph nodes in CRC specimens has increased over the 
years (from 15% in 1996-1997 to 38.9% in 2004-2005 in the U.S.) (Bilimoria et al. 2008) and 
will most likely continue to rise. However, according to UICC criteria, that number is still 
insufficient to guarantee adequate tumor staging. One of the reasons why hospitals fail to 
meet the benchmark of a 12 lymph node yield might be the fact that there are several 
different pathological methods for harvesting lymph nodes, such as manual nodal dissection, 
fat clearing, methylene blue staining or acetone compression, which vary significantly in their 
efficacy of finding lymph nodes. In the following section, each of the above-mentioned 
methods will be described briefly. 
1.4.2 Manual Nodal Dissection and Fat Clearance Methods 
Manual nodal dissection is the technically simplest yet most challenging method of 
harvesting lymph nodes from colon or rectal cancer specimen. As described in a study 
conducted by Jass et al. the rectal cancer specimen is fixed with buffered formaline (4-10%) 
and sliced into 2 to 5mm sections. The nodes are retrieved by inspection and palpation. 
According to Jass et al., about 20 to 30 minutes are required per specimen (Jass et al.1986). 
The difficulty in finding small lymph nodes by using only sight and palpation has already been 
pointed out by Gilchrist and David, who first introduced fat clearance as a new technique to 
harvest lymph nodes from cancer specimens more thoroughly. They used a sophisticated 
method, which is based on the injection of red lead into the superior rectal artery, enabling an 
average harvest of 52.1 nodes per specimen (Gilchrist and David 1938). Based on this now 
historic approach, several other fat clearing techniques have been developed over the years. 
Cawthorn et al. suggest a mixture of ethanol and xylene, by which they were able to retrieve 
a median of 23 nodes per case (Cawthorn et al. 1986). Brown et al. used a slightly different 
approach, termed 'complete submission of the mesentery'. After manually dissecting the 
lymph nodes, the entire remaining mesenteric tissue was treated by elution in a mixture of 
alcohol and acetone, subsequent manual compression with a rolling pin and elution in 
xylene. The remnants were completely encapsulated and embedded in paraffin for histology. 
An average of 20.9 nodes per case was found with gross dissection and a median of 68.6 
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additional nodes was found after complete submission of the tissue (Brown et al. 2004). 
Another approach to enhance the visualization of lymph nodes in fatty tissue is the use of 
Carnoy’s solution, a fixative first described in 1933 by Cutler and Zollinger, which was initially 
used to treat cysts and fistulae (Kumar et al. 2013). Carnoy’s solution, a mixture of 
chloroform, ethanol and glacial acetic acid, facilitates lymph node retrieval by decolorizing 
nodes, thus enabling the harvest of more (22 vs 8) and smaller nodes than using standard 
formaldehyde fixation (Luz et al. 2008). 
1.4.3 Methylene Blue Injection 
To further improve and facilitate lymph node harvest, another pathologic technique was 
introduced: methylene blue injection, first described by Hermanek et al. Originally, methylene 
blue was injected into the superior rectal artery to check for defects in the mesorectal fascia 
after TME to ascertain the thoroughness of the surgery (Hermanek et al. 2003). Märkl et al. 
have taken up this method to increase lymph node yield in CRC specimens, proceeding by 
injecting 15 to 20ml methylene blue solution (50mg diluted with 0.9% saline, ratio 1:3) into 
the superior rectal artery to contrast the lymph nodes. The specimen is fixed in 10% formalin 
for 24 hours. Next, it is cut into 5 to 7mm thick slices, before the whole mount technique is 
used to embed representative areas. The remaining fat is dissected and visible lymph nodes 
are harvested using sight and palpation. Finally, the tissue is embedded in paraffin, stained 
with hematoxylin and eosin, and the slides are examined for metastases. Using methylene 
blue injection, Märkl et al. were able to harvest an average of 27 nodes per case (Märkl et al. 
2007).  
1.4.4 Acetone Compression 
Along with the aforementioned techniques, acetone compression is another, relatively 
recently developed method for best possible lymph node yield, first introduced by Basten et 
al. The basic idea behind this technique is to accelerate and simplify the process of 
harvesting lymph nodes by decreasing the amount of fatty tissue to about 10% of the initial 
weight while still ensuring the same quality of histological sections as conventional methods 
do. The combination of perforating the tissue with a nail roll, soaking it in acetone and finally 
compressing it with a squeezing machine results in the removal of most of the fatty tissue. 
The remaining tissue, the pellet, still contains lymph nodes, nerves and blood vessels. The 
pellet is placed in tissue capsules before being embedded in paraffin, sectioned and 
mounted on glass slides for histopathologic evaluation (Basten et al. 2010). Acetone 
compression allows complete embedding of the entire mesorectal tissue without previous 
manual examination, requiring a relatively short processing time and also guaranteeing the 
harvest of an increased number of lymph nodes as compared with manual dissection or the 
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fat clearance method (Gehoff et al. 2012a). Table 1.3 shows an overview of historic and 
current histopathological methods for lymph node retrieval in CRC specimens.  
Overview of Historic and Current Histopathological Lymph Node Retrieval in CRC: 
Table 1.3 
 
Method Year of description Relevant papers regarding this 
method 
Manual node dissection 1986 Fat Clearance Method Versus 
Manual Dissection of Lymph Nodes 
in Specimens of Rectal Cancer, 
Jass et al. 1986 
Fat clearance method using 
red lead 
1938 Lymphatic Spread of Carcinoma of 
the Rectum, Gilchrist and David 
1938 
Fat clearance method using 
xylene 
1986 Clearance Technique for the 
Detection of Lymph Nodes in 
Colorectal Cancer, Cawthorn et al. 
1986 
Complete submission of the 
mesentery (fat clearance 
method using acetone and 
xylene) 
2004 Efficacy of Manual Node Dissection 
of Lymph Nodes in Colon Cancer 
Resections, Brown et al. 2004 
Methylene blue injection 2007 Methylene Blue Injection into the 
Rectal Artery as a Simple Method 
to Improve Lymph Node Harvest in 
Rectal Cancer, Märkl et al. 2007 
Carnoy’s solution 2008 Carnoy’s Solution Enhances 
Lymph Node Detection: an 
Anatomical Dissection Study in 




2010 Preoperative Chemoradiotherapy 
Does Not Necessarily Reduce 
Lymph Node Retrieval in Rectal 
Cancer Specimens- Results from a 
Prospective Evaluation with 
Extensive Pathological Work-Up, 
Sprenger et al. 2010 
Acetone compression 2010 Acetonkompression, Basten et al. 
2010; Optimal Lymph Node 
Harvest in Rectal Cancer (UICC 
Stages II and III) after Preoperative 
5-FU-based Radiochemotherapy. 
Acetone Compression is a New 
and Highly Efficient Method, Gehoff 
et al. 2012a 
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1.5 Hypotheses 
The nodal status of patients with CRC has a crucial impact on tumor stage, therapeutic 
decisions and the patient's prognosis. However, the efficiency of lymph node yield varies, 
especially in patients treated with preoperative RCT.  
This study focuses on the macropathelogical procedure Acetone Compression for the 
comprehensive retrieval of lymph nodes from rectal cancer specimens. The main hypotheses 
are: 
1. Does Acetone Compression alter the morphology of lymph nodes? 
2. Can Acetone Compression be used to investigate the impact of preoperative RCT on 
lymph node sizes and numbers? 
3. Does the application of Acetone Compression affect the pathological staging of lymph 
nodes? How does the efficiency and performance of Acetone Compression vary compared to 
previous studies? 
 
The three hypotheses are interrelated and can only be addressed cohesively. To address the 
hypotheses, collections of rectal cancer specimens worked-up either with Acetone 
Compression, Manual Dissectioning or with Whole Mesorectal Embedding are digitally 
measured. The resulting morphological descriptors for each lymph node are considered in 
relation to the mode of preparation, preoperative treatment, clinical response and to the 




Device Name Manufacturer 
Arbor press Quantum Arbor Press, DDP2 Stürmer Werkzeuge Maschinen 
KG, Hallstadt, Germany 
Autostainer for IHC BenchMark Ultra Ventana Medical Systems, 
Tucson, AZ, USA 
CCD photo scanner with 
transillumination unit 
Scanjet G4050 Hewlett Packard, Palo Alto, CA, 
USA 
Cold plate OTS 40 Medite GmbH, Burgdorf, 
Germany 
Dehydration machine Shandon Excelsior ES Tissue 
Processor 
Thermo Fisher Scientific GmbH, 
Schwerte, Germany 
Drying cabinet UNE 400 Memmert GmbH, Schwabach, 
Germany 
Embedding center TES 99 Medite GmbH, Burgdorf, 
Germany 
Film Coverslipper Tissue-Tek Film Sakura Finetek Germany GmbH, 
Staufen, Germany 
Freezer, -20°C Liebherr "Premium" Product 
line 
Liebherr Gruppe, Biberach an der 
Riss, Germany 
Fridge, 4°C Liebherr "Premium" Product 
line 
Liebherr Gruppe, Biberach an der 
Riss, Germany 
Instruments for Gross 
Examination 
"Aesculap" Surgical Scissors, 
Forceps, Probes 
B. Braun AG, Melsungen, 
Germany 
Magnetic stirrer and hot 
plate 
MR Hei-Standard Heidolph Instruments GmbH, 
Schwabach, Germany 
Microscope Ecliple 80i with Plan Fluor 
Objectives (1x, 4x, 10x, 20x, 
60x) 
Nikon, GmbH Germany, 
Düsseldorf, Germany 
Pipetts Eppendorf Research Plus Eppendorf AG, Hamburg, 
Germany 
Rotation microtome HM 355 S MICROM International GmbH, 
Walldorf, Germany 
Scale, digital, De=0.1g Kern-PCB6000-1 Satorius GmbH, Göttingen, 
Germany 
Staining machine, HE HMS 760X MICROM International GmbH, 
Walldorf, Germany 
Staining machine, PAS, 
EvG 
COT 20 Medite GmbH, Burgdorf, 
Germany 




Description Name Manufacturer 
Blades for microtome Typ A35, Typ 130S Feather 
Embedding cartidges Universal embedding 
cartridge 
Engelbrecht Medizin- und 
Labortechnik GmbH, 
Edermünde, Germany 
Glass slides (76x26x1mm) StarFrost Engelbrecht Medizin- und 
Labortechnik GmbH, 
Edermünde, Germany 
Glass slides (76x26x1mm) StarFrost Engelbrecht Medizin- und 
Labortechnik GmbH, 
Edermünde, Germany 
Medical Examination gloves Nitra-Tex Ansell Healthcare Europe, 
Brussels, Belgium 
Paraffin Sasol-Wax Sasol, Hamburg, Germany 
Tissue Dye for Grossing CDI Tissue Marking 
Dyes 
Cancer Diagnostics Inc, 




Acetone 99.5% Carl Roth GmbH und Co. KG, Karlsruhe, 
Germany 
Eosin 0.5% solution Engelbrecht Medizin- und Labortechnik 
GmbH, Edermünde, Germany 
Ethanol 100% (fully denatured) ChemLogistics GbR, Düren, Germany 
Isospropyl alcohol 100% ChemLogistics GbR, Düren, Germany 
Mayer's Hemalum solution Merck KGaA, Darmstadt, Germany 
Periodic Acid Merck KGaA, Darmstadt, Germany 
Schiff's Reagent Engelbrecht Medizin- und Labortechnik 
GmbH, Edermünde, Germany 
Xylene 100% ChemLogistics GbR, Düren, Germany 
 
2.4 Primary Antibodies 
Name Target Protein Clone Buffer Dilution Manufacturer 
CK pan  Cytokeratines AE1+AE3 CC1 1:100 Zytomed Systems 
CK20 Type I 
Cytokeratine, 20 
Ks20.9 CC1 1:200 Medac 
CD31 PECAM-1, 
Endothelium 
JC70 CC1 1:100 Cellmarque/Medac 
D2-40 Podoplanin, 
Lymphatics 
D2-40 CC1 1:40 Signet/DCS 
"CC1": Antigen Retrieval Buffer "cell conditioning 1" by Ventana Medical Systems, tris-
buffered, pH=8.0 
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2.5 Secondary Antibodies 
Secondary antibodies were part of ready-made kits. The kit includes a polymer, which is 
conjugated to anti-mouse and anti-rabbit antibodies and to either horse raddish peroxidase to 
produce DAB by oxidation or to alkaline phosphatase to produce a naphtol red dye by 
hydrolysis. The polymer method increases the sensitivity of IHC-staining as several enzymes 
are recruited to the site of a bound primary antibody. 
2.6 Software 
Name Manufacturer 
Image J, Version 1.45s on Java 1.6.0_20 
(32bit) 
National Institutes of Health, Bethesda, MD, 
USA, http://rsb.info.nih.gov/ij/ 
‘R’, language for statistical programming, 
Version 2.13.1 
R Foundation for Statistical Computing, 
Vienna, Austria, http://www.R-project.org  
 









Universal DAB Detection kits Ventana Medial Systems Inc, Tucson, AZ, 
USA 
ultraView Alkaline Phosphatase Red 
Detection kits 




3.1 Patient Population 
 
 WME AC MD 
Cases 51 138 131 
Lymph nodes 1,759 3,624 3,140 
Sex (m/f) 14/37 43/95 47/84 
Age, mean  63.2 (±10.5) 67.7 (±12.5) 67.9 (±10.6) 
T1+ T2 11 (21.5%) 48 (34.8%) 40 (30.5%) 
T3+ T4 32 (62.7%) 70 (50.7%) 82 (62.6%) 
N+  14 (27.5%) 43 (30.1%) 54 (41.2%) 
M1 5 (9.8%) 10 (7.2%) 9 (6.9%) 
Neo treatment 51 (100%) 85 (62%) 68 (52%) 
ypT0 8 (15.7%) 13 (15.3%) 4 (5.9%) 
Table 3.1: Overview of the Study Population’s Clinical Parameters ("N+": node-positive cases, "M1": 
distant metastasis, "neo treatment": application of preoperative RCT, "ypT0": pathological remission after 
preoperative RCT). 
 
Table 3.1 constitutes an overview of the clinical parameters of the patient population in this 
study, which consists of 320 cases of patients with rectal carcinoma UICC stage I to IV. The 
lymph nodes were retrieved from the surgical specimens using three different techniques of 
pathological workup: 51 cases were examined using whole mesorectal embedding (WME), 
138 cases were examined using acetone compression (AC) and 131 cases were examined 
using manual dissectioning (MD). The 51 patients of the WME group were treated at the 
University Hospital of Göttingen, Germany, as part of the CAO/ARO/AIO-2004 study. 
Histopathological examination of this group was also performed at the University Hospital in 
Göttingen. The 269 patients in the AC and MD group were treated at six different hospitals in 
Kassel, Germany; the histopathological examination was performed in one laboratory: The 
Institute of Pathology Nordhessen, Kassel. Patients in the AC group were treated between 
2009 and 2012; patients in the MD group were treated between 2005 and 2012. The median 
age of patients in the WME group was 63.2 (±10.5) years, in the AC group 67.7 (±12.5) years 
and in the MD group 67.9 (±10.6) years. 43 patients in the AC group were female (31%) and 
95 male (69%). 47 patients in the MD group are female (36%) and 84 male (64%). 
Depending on their tumor stage, the patients either received primary surgical treatment or 
preoperative radiochemotherapy (RCT) followed by surgery. All patients in the WME group 
(100%), 85 (62%) of the patients in the AC group and 68 (52%) in the MD group received 
neoadjuvant radiochemotherapy. After pretreatment with RCT, 13 (15.3%) of the patients in 
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the AC group and 4 (5.9%) of the patients in the MD group were diagnosed with pathological 
complete response (ypT0), i.e. histologically no vital tumor cells were present anymore. 48 
patients (34.8%) in the AC group were diagnosed with T1 or T2 tumors, and 70 patients 
(50.7%) were diagnosed with T3 or T4 tumors. In the MD group, 40 patients (30.5%) were 
classified as T1 or T2 and 82 patients (62.6%) were classified as T3 or T4. 14 patients 
(27.5%) of the WME group, 43 (30.1%) of the AC group and 54 (41.2%) of the MD group 
showed lymph node metastasis in the investigated specimens. Distant metastases were 
clinically reported in 10 patients (7.2%) of the AC group and 9 patients (6.9%) of the MD 
group.  
3.2 Definition of Lymph Nodes 
3.2.1 The Histological Structure and Function of Lymph Nodes  
Lymph nodes are small lymphoid organs, spread throughout the entire human body. Typical 
locations for aggregations of lymph nodes are the neck, the axilla or the groin. Lymph nodes 
can be regarded as collecting basins for the intercellular fluid from an adjacent organ or body 
region. Each node has multiple feeding vessels and one draining vessel. Lymph fluid 
coalesces via lymphatic vessels in the thoracic duct, which mainly collects lymph of the lower 
extremities, abdomen, thorax, left arm and left side of the head, and the right lymphatic duct, 
which mainly collects lymph from the right arm, right side of the head and the neck, emptying 
into the left and right subclavian vein and transporting lymph fluid back to the blood stream.  
Lymph nodes are usually round or kidney-shaped and covered with a dense fibrous capsule. 
Parts of the capsule, the trabeculae, extend into the node. Several lymphoid vessels, the 
vasa afferentia, perforate the node’s capsule and emit lymphatic fluid into the sinuses. The 
lymph fluid passes through a system of sinuses, consisting of the subcapsular marginal 
sinus, the cortical sinus and finally the medullary sinus, which drains into the efferent 
lymphatic vessel. The efferent lymphatic vessel exits the node at the hilus, accompanied by a 
venous and an arterial vessel. The interior of a node is lined with reticular connective tissue 
and can be subdivided into cortex, subcortical zone and medulla.  
The cortex mostly contains B-cells, arranged as lymphoid follicles, which can present as 
primary, secondary or tertiary lymphoid follicles. Primary lymphoid follicles consist of reticular 
cells, follicular dendritic cells (fDCs) and naïve B-cells that have not been presented with 
antigens yet. Secondary lymphoid follicles contain a marginal wall with naïve B-cells and a 
germinal center with activated B-cells, follicular dendritic cells, T-cells and macrophages. 
FDCs collect antigens in a major histocompatibility II (MHC II) independent manner and 
present them to adjacent B-cells. B-cells with a matching receptor are activated and 
proliferate within the germinal center, which is histologically distinguishable. The proliferating 
B-cells undergo somatic hypermutation to increase the affinity of the B-cell receptor. Cells 
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with unsuitable receptors undergo apoptosis, which causes a recognizable subdivision of the 
germinal center: Proliferating cells form a darker half of the germinal center, while 
predominant apoptosis causes the other half of the germinal center to appear lighter.  
The paracortical zone of the lymph nodes is located in between and underneath the lymphoid 
follicles and contains mostly T-cells, MHC II-positive dendritic cells and high endothelial 
venules. Most of the T-cells exit the blood stream by penetrating the venules and remain in 
the paracortical zone where they can be activated by antigen-presenting dendritic cells. The 
medulla of the node contains medullary cords, where plasma cells and macrophages are 
located.  
The composition of lymphoid fluid is equivalent to tissue fluid when entering the node. Since 
the main functions of lymph nodes are to preserve a physiological intravascular pressure and 
guarantee an adequate immune response, the majority of antigens are removed from the 
lymphoid fluid during passage through the nodes while immunoglobulins and lymphocytes 
are added. Analogical neoplastic cells detached from a solid tumor may be displaced to 
regional lymph nodes via lymphatic vessels of the affected organ. Given the flow of the 
lymph, these neoplastic cells are likely to arrive at and be stuck in the marginal sinus from 
where they may start infiltrative growth and give rise to lymph node metastases. As any 
tissue, lymphocytes themselves may also undergo malignant transformation. Depending on 
the cell of origin and their respective maturation state, distinct forms of lymphoma result.  
Thus, the swelling of lymph nodes is a prominent clinical symptom, which may either reflect a 
physiological reaction of the lymphatic tissue to an infectious agent or it may be a symptom 
of malignancy. If the latter cannot be ruled out with clinical examinations, needle biopsy or 
bioptic sampling of a lymph node may be indicated to determine the origin of the swelling by 
histopathological analysis. Conversely, comprehensive lymph node examination is an 
integral part of the pathological staging of solid tumors (Welsch 2010 chapter 6, p.243-246; 
Lüllmann-Rauch 2009 chapter 13, p.311-313). 
3.2.2 Criteria for Determination of Lymph Nodes  
In the comprehensive examination of lymph nodes it is important to define the histological 
criteria of what constitutes a lymph node. Lymph nodes are dynamic structures which expand 
and diminish on demand. Given the aforementioned microstructure of lymph nodes, four 
criteria for the identification of lymph nodes were determined (Figure 3.1, Table 3.2). To 
qualify as a lymph node, at least two of the four criteria had to be recognizable: the shape of 
the lymph node, which is typically round or kidney-shaped, the histological structure of the 
node with lymphoid follicles, the presence of a capsule and the presence of blood vessels 
such as venules or afferent and efferent lymphatic vessels in the lymph node. These criteria 






















Lymphoid infiltrate may mimic lymph nodes by forming follicular structures and by their being 
located close to blood vessels. However, these infiltrates are not part of the lymphoid fluid 
transportation system and thus not the target of metastatic spread. The four criteria (Table 
3.2) were also found to be present in tiny lymph nodes (<1mm), yet are never mimicked 
simultaneously by lymphoid infiltrate. Figure 3.1 illustrates an archetypical lymph node 
featuring all four criteria. In questionable cases, the four criteria can be determined by means 
of immunohistochemistry (IHC). Figure 3.2 A shows a representative tiny lymph node after 
retrieval with acetone compression. The lymphatic vessels (Figure 3.2, A2) may be 
contrasted by using IHC-staining against podoplanin, while blood vessels (Figure 3.2, A3) 
show a positive reaction to CD31-staining. In contrast, lymphocytic infiltrate (Figure 3.2, B) 




Criterion Typical feature 







follicles (B), medullary 
cords (E) 
3. Capsule and 
marginal sinus 
(D) 
Collagen fibers (type-I 
collagen), fibroblasts, 
elastic fibers 





Table 3.2 The Criteria for Identification of Lymph 
Nodes (as shown in Figure 3.1) 
Figure 3.1 Typical lymph node. B: 
Lymphoid follicles. C: Hilum vessels. D: 




Figure 3.2 A selection of figures of lymphoid structures stained with IHC 
A1-3: The morphology is preserved during AC and the defining structures may be verified by immunohistochemistry (A1, 20x, 
method: AC): marginal sinus and feeding lymphatic vessels (A2, IHC: podoplanin/ D2-40), hilum artery (A3, IHC: CD31). B: An 
example of lymphatic aggregates not showing any of the 4 defining structures (20x).  
C1: Macrometastasis with glandular architecture of the malignant infiltrate (10x, method: MD). C2: Macrometastasis with 
extensive extracellular mucus (20x, method: MD). D1, D2: Micrometastasis detected after AC (D1, HE; D2, IHC: CK20; 50x). 
E1-4; F1-3: The regression of malignant infiltrate after neoadjuvant chemoradiotherapy. E1: Node with vital infiltrate (right) next 
node with sclerosis and remnants of infiltrate (10x). E2: IHC for CK20 contrasts vital tumor cells in both nodes (10x). Details for 
right node (E3, 100x) and left node (E4, 100x). F1: Lymph-node showing fibrotic and sclerotic tissue (10x). Higher magnification 
reveals remnants of vital tumors cells (F2, 100x), IHC for CK20 contrasts more infiltrates (F3, 10x) and isolated tumor cells that 
separate from the the glandular structures (magnified insert).  
G: Angioinvasion in a venous vessel after AC. The vessel is obstructed by malignant infiltrate. The accompanying artery is seen 
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next to the vein. H1-3: Perineural invasion after AC. Malignant infiltrates adjavent to nervous strands (H1, HE, 20x). Double-IHC 
for panCK (red) and CD31 (brown) demonstrated extensive perineural invasion (center); isolated CK-positive tumor cells are 
present in a CD31-positive vessel (top). The peripherial nerves are S100 positive (I3). 
3.3 The Histopathological Workup of CRC Specimens 
In the following paragraphs (3.3.1 - 3.3.6)  gross examination, dissectioning, embedding, and 
histological and immunohistochemical staining are described, which were performed by 
certified pathologists at the Institute of Pathology Nordhessen in Kassel (Acetone 
Compression, Manual Dissectioning) and at the University Hospital Göttingen (Whole 
Mesorectal Embedding). 
3.3.1 The Dissection of CRC Specimens 
Gross examination and dissectioning were performed according to standard protocol. Cases 
with AC and MD retrieval of lymph nodes were examined at the Institute of Pathology 
Nordhessen in Kassel. The cases with WME retrieval were examined at the University 
Hospital in Göttingen. Except for the differences in lymph node preparation, the dissectioning 
of the rectum was performed identically. First, the colorectal cancer specimen was 
macroscopically inspected, and the quality of the total mesorectum excision (TME) was 
judged. The mesorectum is regarded as a "continuity of the mesosigmoid" (Hoorens et al. 
2009, p.252) and its complete removal is an important factor in the risk evaluation of local 
recurrence (Heald et al. 1982). This was already recognized by the phase II CORE study, 
which suggested assessing the thoroughness of the surgery based on a grading system 
ranging from Grade 1 (incomplete/poor) to Grade 3 (complete/good) (Maughan and Quirke 
2003). The MERCURY study, performed in 2002, compared Magnetic Resonance Imaging 
(MRI) prior to surgery and post-operative pathologic assessment of rectal cancer patients in 
predicting successful surgical resection (MERCURY Study Group 2006). These studies 
established criteria for the assessment of the TME quality, which are now diagnostic 
standard, the so-called M.E.R.C.U.R.Y criteria: The good quality of the TME features an 
intact mesorectum with only few irregularities. No defect is deeper than 5mm and there is no 
coning towards the distal margin. If the specimen shows a moderate amount of mesorectum 
with irregularities on the surface of the mesorectum, the quality of the TME is considered 
moderate. There is moderate coning, and the lamina muscularis propria is not visible. If the 
quality of the TME is assessed as poor, only little mesorectum remains and there are defects 
as far as the lamina muscularis propria. The TME is classified as incomplete if the muscular 
layer is visible and the specimen shows perforation. Additionally, the circumferential 
resection margin (CRM) should be assessed. The CRM represents the area of the specimen 
closest to the deepest infiltration of the tumor and a positive CRM is defined as the tumor 
being located less than 1mm from the CRM (Hoorens et al. 2009). Statements about the 
tumor involvement of the CRM are required since a positive CRM has proven to be a 
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significant risk factor in the local recurrence of rectal cancer (Quirke and Dixon 1988). To 
evaluate the CRM, the mesorectum is marked with xylene-resistant ink. The specimen is 
longitudinally opened by cutting from proximal to distal. Cutting through the tumor is avoided 
by careful palpation. Now the distance of the tumor from the oral and aboral resection margin 
can be measured. Subsequently, the tumor area is sliced into transverse sections. The size 
of the tumor area, the depth of infiltration and the distance of the tumor from the resection 
margin are measured. The depth of infiltration as far as it is macroscopically visible is 
documented. The specimen is cut into pieces of 2 to 4mm in size, and several blocks are 
selected for histology. The region of deepest tumor infiltration is also selected for histology to 
verify the depth.  
The lymph nodes in the sliced tumor regions that are visible upon macroscopic inspection, as 
well as large, palpable nodes from the whole specimen are manually retrieved and 
embedded in paraffin. The remaining fatty tissue is removed from the rectum and lymph 
nodes can be retrieved using one of the three following techniques: manual dissectioning by 
slicing, palpation and inspection; fat clearance by elution in a mixture of solvents overnight 
and subsequent manual dissectioning or acetone compression by combined elution in pure 
acetone and mechanical compression. An experimental approach is the whole mesorectal 
compartment embedding (WME) of the entire fatty tissue without pretreatment of the 
specimen. The pathological assessment of the colon cancer resection specimen is handled 
in a similar manner, with the exception of the quality assessment of the TME as this is a 
procedure only performed on carcinoma of the rectum.  
Figure 3.3: An example of the rectal cancer specimen of case #116. A, B: opened specimen, front and back. C: 
tumor region D: tumor region close-up with depth of infiltration visible 
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3.3.2 Tumor Regression Grading 
Tumor regression is regarded as a reflection of the treatment response of the tissue to 
preoperative radiochemotherapy. It is assessed by the microscopic examination of glass 
slides containing sections of the tumor area and can be classified according to different 
systems. Currently, the most commonly used system is the one established by Dworak et al. 
(Dworak et al. 1997) and ranges from Grade 0 (no regression) to Grade 4 (complete 
regression): 
− Grade 0: no regression 
 
− Grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy 
 
− Grade 2: dominantly fibrotic changes with few tumor cells or groups (easy to find) 
 
− Grade 3: very few tumor cells (difficult to find microscopically) in fibrotic tissue 
with or without mucous substance 
 
− Grade 4: no tumor cells, only fibrotic mass (total regression or response) 
 
3.3.3 Advanced Lymph Node Retrieval: WME and Acetone Compression 
51 of the 320 cases in this study were examined using the whole mesorectal embedding 
technique (WME) for the complete workup of the mesorectal fatty tissue. It may be regarded 
as reference standard since it allows the retrieval of virtually all lymph nodes without 
additional tissue alteration. On the other hand, it is too time and resource consuming to be 
used in daily pathological practice. The WME-cases analyzed here are part of a study 
mentioned earlier (Sprenger et al. 2010). In brief, the specimens were opened longitudinally 
along the rectal lumen and fixed in 5% formalin for 72 hours. No additional preconditioning of 
the fatty tissue was performed. For macroscopic grossing, the specimen was sliced into 5mm 
cross-sections. For paraffin-embedding, the cross-sections were again divided into 2.5mm 
slices. To avoid causing a misleadingly high number of lymph nodes, care was taken not to 
embed both halves of the cut lymph nodes (Sprenger et al. 2010). 138 of the remaining 269 
cases were examined, using acetone compression (AC) according to the procedure 
published by Basten et al. (Basten et al. 2010, Gehoff et al. 2012a). AC is a recent 
advancement in techniques used to enhance lymph node retrieval by means of using 
solvents and mechanical procedures. The use of acetone was described by Brown et al. in 
2004: acetone in combination with alcohol was used as a solvent for mesenteric fat. The 
mesenteric fat was washed daily with a graduated series of alcohol and acetone over several 
days to dehydrate the tissue before soaking it in xylene for another day (Brown et al. 2004). 
The use of pure acetone in combination with mechanical compression was first developed 
and described by Basten et al. in 2010 and applied in a slightly altered manner in the present 
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study: the fatty tissue was carefully dissected and weighed after macroscopic inspection of 
the specimen. It was inspected for palpable and visible lymph nodes, which were manually 
harvested. After the fatty tissue was perforated with a needle roller, it was soaked in acetone 
for 12 hours. The acetone used was disposed of, and the tissue was perforated again before 
elution in acetone for another 4 to 6 hours. The tissue was twitched into pieces of 3 to 5cm in 
size and placed in a "brazen cylindrical tube with multiple small perforations" (Gehoff et al. 
2012a, p.205). The tissue was then manually compressed with the help of an arbor press 
(Quantum Arbor Press). While the tissue was being compressed, fat and acetone leaked out 
of the perforations in the tube, thus resulting in a reduction of the initial tissue weight of up to 
95% (fatty tissue with a weight of 300g prior to AC can weigh as little as 20g after 
compression). Despite the considerable weight reduction, the remaining tissue, the so-called 
pellet, still contained fully-preserved lymph nodes, vessels and nerve structures. As usual, it 
was encapsulated usually with 1g of tissue per capsule and transferred to routine 
embedding. Basten et al. used heated acetone at a temperature of up to 56 degrees for 
elution. However, the use of heated acetone has proven not only to make cutting the tissue 
blocks difficult but also to result in IHC stainings of low quality due to "more unspecific 
background staining" (Gehoff et al. 2012a, p. 207).  These drawbacks can be compensated 
for by using acetone at room temperature as was done in this study.  
3.3.4 Embedding and Manufacturing of Paraffin Blocks 
In order to proceed with the histopathological evaluation, it is necessary to embed the 
examination material. Embedding takes place overnight in a dehydration machine (Shandon 
Excelsior ES Tissue Processor), where the material is incubated with 4% formaldehyde, 70% 
isopropyl, 96% isopropyl, 100% isopropyl, xylene and finally paraffin. By elution of the 
material in alcohol of increasing concentrations, water and tissue fluid are gradually removed 
and replaced with a wax such as paraffin, which strengthens and preserves the tissue. After 
embedding the material in paraffin with help of an embedding center (TES 99), paraffin 
blocks are manufactured, which are then cut using a microtome (HM 355 S). The paraffin 
block is inserted into the microtome and sections of 1 to 1.5µm size are cut. The sections 
slide from the microtome blade onto the surface of a water bath, which is heated to room 
temperature to prevent them from wrinkling. Each section is captured on a glass slide and 
put on the surface of a second water bath. The section expands and is captured again on a 
glass slide with a refined surface that enables strong adhesion ("StarFrost"). Once they are 
dry, they are available for histochemical and immunohistochemical stains. After sectioning, 
paraffin blocks are stored in cardboard boxes for a period of at least ten years. 
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3.3.5 Histological Staining  
After the paraffin sections are mounted onto glass slides, they are stained for further 
histopathological examination. Prior to being staining, the sections have to be rehydrated and 
the paraffin must be removed as it would prevent the sections from taking on color. A 
descending alcohol series is performed:  
 
Substance Duration 
Xylene 10 minutes 
Xylene 5 minutes 
100% Isopropyl 1 minute 
100% Isopropyl 1 minute 
96% Isopropyl 1 minute 
90% Isopropyl 1 minute 
70% Isopropyl 1 minute 
Distilled water Until the staining process starts 
  
 
Since the different components of tissue vary in their electric charge, it is essential to use a 
stain that dyes structures that are both basophilic (such as the DNA) and acidophilic (such as 
the cell nucleus). The most common stains used in histology are hematoxylin and eosin 
(H&E). Hematoxylin, a basic substance, allows the staining of anionic structures that adopt 
red color, while eosin, an acid substance, allows the staining of cationic structures that adopt 
blue color (Lüllmann-Rauch 2009). H&E was performed in the staining machine (HMS 760X 










Staining takes place in aqueous solution. Afterwards, the sections are dehydrated again. The 
slides were sealed using a coverslipper machine (Tissue-Tek Film).    
 
Substance Duration 
Warm tap water 1X 1minute 
Hemalaun   4X 1minute 
Warm tap water 3X 1minute 
1% Eosin 1X 1minute 
96% Isopropyl 2X 1minute 
100% Isopropyl 2X 1minute 








3.3.6 Immunohistochemical Staining  
Immunohistochemical staining allows for the identification and visualization of structures that 
can be bound by specific antibodies. IHC is used, for example, to verify the presence of DNA 
mismatch repair enzymes, such as MLH1 or MSH2 in CRC patients and thus exclude a DNA 
mismatch repair deficiency typical for HNPCC. IHC can be performed using a direct or an 
indirect approach. The indirect approach involves two antibodies, a primary antibody that 
binds to an epitope of the antigen in question, and a secondary antibody that reacts with the 
fc-fragment of the primary antibody. Visualization is achieved by coupling an enzyme either 
to the primary antibody (direct IHC) or to the secondary antibody (indirect IHC). When the 
appropriate substrate is added, the enzyme will catalyze the formation of a chromophore at 
the side of the antigen-antibody complex. IHC was performed by preparing 1µm sections as 
described above. After the removal of paraffin with xylene, the sections are incubated with 
alcohol in decreasing concentrations. While soaking in 50% Isopropyl, hydrogen peroxide 
was added. This 'peroxide-block' results in blocking of the activity of endogenous peroxidase 
and thus prevents non-specific background-staining of the sections. Immunohistochemical 
staining takes place in immunostainers (Optimax or BenchMark Special Stains). Formalin 
fixation not only preserves material but may also cause the cross-linking of proteins, thus 
hampering their immunoreactivity. The so-called antigen retrieval is prerequisite to IHC: heat-
incubation at a certain pH-value or enzymatic digestions 'unmask' a given epitope by 
removing such cross-links. Antigen retrieval was generally performed by heat-incubation in a 
water bath. Temperature, incubation time and buffer/pH were optimized for each antibody. 
Detection was performed ultraView Universal DAB Detection kits (Ventana Medial Systems 
Inc, Tucson, USA, vgl. http://www.ventana.com/documents/ultraViewDABbrochure.pdf), 
Figure 3.4 Example of H&E staining: glass 
slides from case # 50 
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which rely on the oxidation of 3,3’-Diaminobenzidine (DAB). The secondary antibodies and 
the horse raddish peroxidase (HRP) are bound to a polymer to increase the recruitment to 
the primary antibody. HRP oxidizes DAB, which makes it insoluble in an aqueous solution. 
DAB-precipitates form at the antigen-antibody complex yielding a brownish-black stain.  
Double-IHC was achieved by performing the staining procedure again and using ultraView 
Alkaline Phosphatase Red Detection kits (Ventana Inc), which use the enzyme Alkaline 
Phosphatase (AP) to hydrolyze Naphtol Red into an insoluble red azo dye. The sections 
were counterstained with hematoxylin before they are covered and forwarded to 
histopathologic assessment.  
3.4  Morphometric Analysis of Lymph Nodes 
In the following two paragraphs (3.4 and 3.5) microscopical examination and morphometric 
analysis of the lymph nodes as well as statistical analysis are described, which were 
performed by Rebecca A. Reineke under supervision of PD Dr. med. P. Middel and Dr. med. 
A. Scheel.                  
To ensure standardized conditions, the lymph nodes of all 320 cases were evaluated again 
based on the aforementioned morphological criteria (Table 3.2). Every glass slide of each 
case was microscopically examined using an Eclipse 80i microscope (Nikon, Japan) and 
Fluor Objectives (1x, 4x, 10x, 20x, 40x, 60x). The number of lymph nodes and lymph node 
metastases was noted on the respective glass slide. Each lymph node was checked for 
integrity. For positive lymph nodes, the amount of tumor infiltration (0 to 25%, 26 to 50%, 51 
to 75%, 76 to 100%), extracapsular growth and the morphologic structure of the malignant 
tissue were documented. Additionally, several morphological parameters were recorded: the 
extent of extracellular mucus (no mucus, 0 to 50% of the tumor area, 51 to 100% of the 
tumor area) and the presence of inflammatory infiltration and necrosis were evaluated.  
The slides were subsequently digitalized using a charge-coupled device-scanner with 
transillumination adapter (Scanjet G4050). The device allows for the simultaneous scanning 
of 3 rows of 7 glass slides, i.e. 21 slides per run. As a compromise to accuracy and speed, 
the resolution of the Scanjet G4050 scanner was set to 200 dots-per-inch (dpi). At this 
setting, one inch (25.4mm) is represented by 200 pixels, i.e. 7.87 pixels per millimeter. The 
optical properties were verified using a reference scale bar  of 1mm length (Nikon, Japan). 
The bar measured 8 pixels (px) at 200dpi resolution (figure 3.5), thus the measurement 
accurately matched the theoretical prediction. At the highest resolution of 7200dpi, the 1mm 
bar measured 287px. Given the theoretical length of 283.46px, the maximum deviation 
caused by the scanner was calculated to be 1.25%. The morphometric analysis was 
performed using 'Image J' analysis software (http://rsb.info.nih.gov/ij/). The parameters 
 32 
recorded per node are: area, perimeter, bounding rectangle with height and width, fit ellipse 
with minor and major radius, Feret diameter, aspect ratio, roundness and solidity (Table 3.3). 
Parameter Definition, Comments 
Area Calibrated to square millimeters (mm2) 
Perimeter Length of the outside boundary of the selection 
Bounding rectangle, width Width of the minimum bounding rectangle (i.e.. the smallest 
rectangle fitting around the selection) 
Bounding rectangle, height Height of the minimum bounding rectangle 
Fit ellipse, major radius Primary radius of the ellipse best fitting around the selection 
Fit ellipse, minor radius Secondary radius of the ellipse best fitting around the selection 
Feret diameter Largest 'caliper' diameter of the selection 










Table 3.3 Overview of the Morphometric Parameters Estimated for Each Lymph Node 
Image J is an open-source software which was developed at the National Institute of Health 
in Bethesda, USA. It provides a highly customizable environment for image analysis in the 
JAVA programming language. Here, the lymph nodes were indicated as regions of interest 
using either the Freehand selection tool or the Elliptical selection tool, depending on the 
shape of the respective node (Figure 3.5). A script was used to perform scale-adjusted 
measurements.  
3.5 Statistical Analysis 
Data were collected using Excel Version 2007 (Microsoft, Redmond, USA). Two tables were 
created: Table 1 contained one row per case and provides a summary of each case and the 
case-related information. Table 2 contained one row per lymph node and was used to record 
the morphometric parameters including number of nodes, number of metastasis and mode of 
lymph node retrieval. The redundancy was used to verify the values.  
Statistical analysis was carried out using 'R' statistical programming language version 2.13.1 
(www.r-project.org). R is available under the GNU general public license (http://www.r-
project.org/COPYING). The following functions are used: 
The data were divided into subgroups using split()of package [base]. Split allows 
separation of a table or of columns of a table by one or several criteria. For example, 
split(AC[,30], AC[,12]>0]$"TRUE" -> AC_nodes will operate on object 'AC' (a 
dataframe containing all cases treated with acetone compression) and separate column 30 
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(Number of lymph nodes for each case) according to column 12 (Type of treatment: 0= 
primary operation, 1= neoadjuvant chemoradiotherapy). The suffix $"TRUE" extracts values 
fulfilling criterion AC[,12]>0 from the results of the function. Thus, a vector containing the 
number of nodes of cases treated with chemoradiotherapy and acetone compression is 
output and mean(AC_nodes)will calculate the average number. Likewise, changing the 
suffix to $"FALSE" will output cases treated with primary operation.  
Statistical functions were provided with the package [stats] while graphical functions for 
drawing diagrams were provided by package [graphics]. Statistical testing was 
performed with Student's t-test ( t.test() ) by assuming normal distributions. Significance 
levels were set to α= 5%.  
Correlations were investigated using cor()set to Pearson's ( cor(x, y, method="p")). 
Linear regressions was calculated with lm() and 2D plots with regression lines were plotted 
using plot() and abline() using intercept and slope from lm().   
Kernel density estimation ( density() ) of the lymph node size was calculated using a 
Gaussian kernel and a rule-of-thumb estimation of the bandwidth ( bw = "nrd0" ). The 






Figure 3.5 The verification of the scanning device  
A precision scale bar of 1.0mm length was digitized at 200dpi (A) and 7200dpi (C). The bar is in the center of the double 
circle. At 7200dpi the subdivisions into 100µm sections are visible (ticks). Quantification with ImageJ yields a length of 8 




Figure 3.6 Lymph node morphometry with ImageJ 
A: Digitized glass slides of case #27 featuring 7 slides with manually dissected nodes (lower row) and 4 slides 
with additional nodes after acetone compression (upper row). Note that no fatty tissue is visible after 
compression, the pink color represents the compacted cell membranes, vessels and matrix. B: Lymph nodes 
were indicated as Region-Of-Interests using the ImageJ free-hand tool and are highlighted green. Inserts: 
Magnifications of indicated region with and without manually drawn outline indicated by green line (A, B: Scan in 
original size at 200dpi, 1mm = 8 pixel. Hematoxylin and eosin staining, two sections per slide. Labels of the slides 
were removed by cropping to exclude patient IDs used for diagnostic purposes. Inserts: Upscaled 3x). 
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4. Results 
4.1 Summary and Study Population 
8,523 lymph nodes of 320 rectal cancer patients treated between 2005 and 2012 were 
analyzed in this study. The patients were treated at six different hospitals in Kassel, 
Germany or at the University Clinic in Göttingen, Germany. Depending on their tumor 
stage, the patients either received radiochemotherapy followed by surgery or primary 
surgical treatment. The clinical parameters of the patients are summarized in Table 3.1. 
The surgical specimens of the patients were prepared using one of three techniques 
available for lymph node retrieval: 51 cases were prepared with whole mesorectal 
embedding (WME), 138 cases were prepared using acetone compression (AC) and 131 
cases were prepared using conventional manual dissectioning (MD). Each case was 
microscopically examined and digitalized, and the morphometric parameters of the lymph 
nodes were assessed. The evaluation of the lymph node morphometry allows the 
comparison of the efficiency of the different lymph node retrieval techniques as well as the 
investigation of the impact of preoperative radiochemotherapy on lymph node size and 
numbers. Figure 4.1 shows a flowchart of the 320 cases of the patient population 
subdivided by technique used for lymph node retrieval as well as the mode of treatment 
(preoperative CRT or primary surgery). The figure also shows the total number of nodes 
harvested with each technique and the mean number of nodes harvested per case (Figure 
4.1). 
Figure 4.1 Overview of the study population: the population is subdivided by technique used for 
lymph node retrieval (WME, AC or MD) and each group is further subdivided by treatment (RCT or 
primary surgery). For each group, the  total number of nodes harvested and the mean number of 
nodes per case is shown 
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4.2 Lymph Node Yield 
4.2.1 Lymph Node Yield according to Preparation 
To test the efficiency of AC, the number of retrieved lymph nodes was assessed and 
compared to the number of lymph nodes found with MD or WME. Additionally, possible 
influence of different pathologists using MD was investigated.  
The total number of lymph nodes harvested was compared between WME, AC and MD 
(Figure 4.2). Using WME, the harvest of 1,759 lymph nodes in 51 cases was achieved, 
resulting in the greatest number of retrieved lymph nodes with an average of 34 (±17) 
nodes per case. In the 138 cases examined with AC, a total of 3,882 of lymph nodes were 
harvested. 257 nodes in the AC group were manually detected prior to AC and 3,625 
nodes were detected after subsequent acetone compression, yielding an average of 28 
(±13) lymph nodes per case. Manual dissectioning led to the harvest of the smallest 
number of lymph nodes with a total of 2,882 nodes in 131 cases, i.e. 22 (±10) nodes per 
case on average (Figure 4.2). The differences in the lymph node harvest between the three 


















Figure 4.3 The number of lymph 
nodes harvested according to 
preparation: 
The dashed line marks the 12-lymph 
node threshold according to the UICC. 
The histogram shows the number of 
cases with a certain number of retrieved 
nodes (ranging from <12 nodes to 81 to 
90 nodes per case) according to the 
techniques used for lymph node harvest 
(WME, AC and MD).  
Figure 4.2 The total number of lymph 
nodes per case according to 
preparation:  
The number of lymph nodes harvested 
per case according to the three methods 
used (WME, AC and MD). WME: 34 




The UICC-recommended minimum of harvesting 12 or more nodes per case was met in all 
of the WME cases (100%). AC succeeded in delivering a minimum of 12 nodes in 129 of 
138 cases (93.5%), and MD in 118 of 131 cases (90%). In Figure 4.3, a histogram shows 
the number of cases with a certain number of nodes harvested (ranging from less than 12 
nodes per case to 81 to 90 nodes per case) according to preparation.  
When  comparing the numbers of lymph nodes found with MD, a difference was noted 
regarding the extent of the lymph node yield of the pathologists responsible. The 
pathological workup of the 131 cases examined with MD took place at the Institute of 
Pathology Nordhessen in Kassel, and was performed by certified pathologists. The lymph 
node harvest of four different pathologists (pathologists 1 to 4), who examined 69 of the 
MD specimens, was compared (Table 4.1). A significant difference in the numbers of lymph 
nodes harvested between pathologist 1 and 2 was noted (p= 0.0048). Pathologist 1 
examined 16 cases using MD and found a minimum of 12 nodes in all 16 cases with a 
mean number of 23.6 nodes per case (SD±6.4). Pathologist 2 examined 17 cases with a 
mean number of 17.3 nodes per case (SD±5.5) and failed to meet the benchmark of 
harvesting at least 12 nodes in 2 of the 17 cases. The lymph node yield obtained through 
pathologists 1, 3 and 4 were comparable though differences in standard deviation (SD) and 
cases with less than 12 nodes examined were noticed: Pathologist 3 examined 17 cases 
and harvested a mean number of 19.2 nodes per case (SD±6.2). One of the cases 
examined by pathologist 3 did not meet UICC criterion. Pathologist 4 examined 19 cases 
with a mean number of 21.7 nodes per case (SD±9.45) and harvested fewer than 12 nodes 








4.2.2 Lymph Node Yield according to Patient Characteristics 
To address potential biases in the data which might affect the apparent performance of the 
different retrieval techniques, the lymph node yields were placed in the context of different 
patient characteristics:  
Pathologist Number of 
cases 
Mean number of 
nodes 
harvested 
SD Number of 
cases with <12 
nodes 
1 16 23.6 6.4 0 
2 17 17.3 5.5 2 
3 17 19.2 6.2 1 
4 19 21.7 9.45 2 
Table 4.1: The Lymph Node Yield Obtained through Conventional Manual 
Dissectioning of Four Different Certified Pathologists at the Institute of 
Pathology Nordhessen, Kassel 
 39 
Figure 4.4 The number of lymph nodes 
retrieved according to age:  
The AC and MD group were subdivided into 
quartiles according to age. No significant 
difference in the number of nodes harvested 
was found between the quartiles.  
 
As several studies have observed a relation between certain patient traits and lymph node 
yield, the number of lymph nodes harvested in this study was also evaluated according to a 
number of patient characteristics, including age, gender, the amount of fatty tissue prior to 
AC and the presence of positive lymph nodes. The mean patient age of the study 
population is 63.2 years in the WME group, 67.7 years in the AC group and 67.9 years in 
the MD group. To evaluate the association between patient age and the number of lymph 
nodes found, AC and MD cases were subdivided into quartiles (Q1 to Q4) according to 
age. Q1 included patients from 23 to 61 years of age, Q2 consisted of patients from 62 to 
70 years of age, Q3 contained patients from 71 to 76 years of age, and Q4 included all 
patients older than 76 years of age. The differences between the quartiles were not 
significant (Figure 4.4). To assess a possible distinction in the lymph node harvest of male 
(n=179) and female patients (n=90) in the AC and MD groups, the number of lymph nodes 
harvested was evaluated according to gender (Figure 4.5). Again, no significant difference 
was found. In the AC group, the weight of the fatty tissue of the specimens prior to and 
after acetone compression was measured and documented. A moderate linear correlation 
was noted between the total number of lymph nodes retrieved and the weight of the fatty 
tissue prior to compression. Pearson’s correlation coefficient was r=0.417 (Figure 4.6). No 
correlation was found between the total number of lymph nodes per case and the number 
of positive lymph nodes (Figure 4.7). No increase in positive lymph nodes was detected if 














Figure 4.5 The number of lymph nodes 
retrieved according to gender:  
The number of lymph nodes harvested was 
assessed according to gender. No significant 
difference between the male (n=179) and the 
female (n=90) patients was found. 
 
Figure 4.7 The number of positive lymph 
nodes retrieved according to the total 
number of nodes harvested:  
There was no increase in the number of positive 
nodes harvested if a greater number of nodes 
were found overall.  
 
Figure 4.6 The number of lymph nodes 
retrieved according to weight of fatty tissue 
prior to AC:  
A linear correlation was found between the 
number of nodes harvested and the weight of 
the uncompressed fatty tissue (Pearson’s 
























4.2.3 Lymph Node Yield according to Treatment 
The lymph node yields were considered in relation to clinical treatment to test the influence 
of preoperative RCT:  
All 51 patients in the WME group were treated with neoadjuvant radiochemotherapy. In the 
AC group, 85 patients (62%) and in the MD group 68 patients (52%) received preoperative 
RCT. The lymph node yield in patients who received preoperative RCT and patients who 
were primarily operated was compared: in the AC group, the administration of neoadjuvant 
RCT did not have a significant impact on the extent of the lymph node yield. An average of 
27 (±12) nodes was harvested in patients treated neoadjuvantly, and an average of 30 
(±15) nodes was found in patients treated with primary surgery (p=0.13) (Figure 4.8). 
In the MD group, neoadjuvant RCT resulted in a significantly smaller number of nodes 
harvested compared to the lymph node harvest in patients who were primarily operated 











Figure 4.8 The lymph node yield 
according to treatment in the AC 
group:  
The mean number of nodes 
according to treatment (neoadjuvant 
RCT or primary surgery). No 
significant difference in the number 
of nodes found was noted between 
the two groups (p=0.13). 
 
Figure 4.9 The lymph node yield 
according to treatment in the MD 
group:  
A significant difference in the mean 
number of nodes found by MD was 
noted between patients who 




4.3 Lymph Node Morphometry 
4.3.1 Lymph Node Morphometry according to Preparation 
To address the main question if the lymph nodes are morphologically altered by AC, 
morphometry of AC and WME cases was compared (hypothesis 1). Since WME does not 
involve treatment with solvents or mechanical stress, it may serve as reference standard 
for lymph node morphology.  
Additionally, the lymph node diameters of cases worked-up with either AC, MD or WME 
were compared to assess the impact of these methods to the sizes of the nodes. 
Next, morphometric characteristics of the lymph nodes were assessed. First, the average 
lymph node sizes were evaluated for each technique. It was found that WME resulted in 
the harvest of the smallest nodes as the mean size (in mm) of lymph nodes in the WME 
group was 2.25 (±1.3). The lymph nodes harvested with AC showed a mean size of 2.27 
(±1.6). While the difference in lymph node size between the WME and the AC group was 
not statistically significant (p=0.105), the nodes harvested with MD were found to be 
significantly larger with a mean size of 3.36mm (±2.0mm, p<0.01). Special attention was 
paid to the harvest of small lymph nodes, i.e. nodes with a maximum diameter of 2mm or 
less. In the WME group, 920 (52%) of all nodes found were smaller than 2mm. AC resulted 
in the harvest of the greatest number of nodes smaller than 2mm (2,099 nodes, 58%), 
whereas MD led to the harvest of the smallest proportion of nodes with a diameter less 
than 2mm (791 nodes, 25%) (Figure 4.11). In comparison to WME and AC, MD resulted in 
the harvest of lymph nodes with the largest diameter (3.36mm). The 257 nodes in the AC 
group found prior to compression showed a mean diameter of 3.38mm, which is 
comparable to the mean diameter of nodes harvested through MD. 
Next, morphologic descriptors were compared between nodes found with WME and AC. 
Unlike the nodes found with AC and MD, the nodes found with WME were not subjected to 
solvents or mechanical procedures and can be regarded as a reference standard. The 
evaluated morphologic descriptors were comparable for the WME and the AC nodes: 
roundness (0.69, 0.68), aspect ratio (1.58 for both groups), mean area (3.47mm², 3.43mm²) 
as well as the mean perimeter (6.3mm, 6.1mm). In Figure 4.10, the lymph node sizes 
according to preparation are depicted as a boxplot. Similar to a histogram, kernel density 
estimation (KDE) was used in Figure 4.12 as a non-parametric way to illustrate lymph node 
sizes according to preparation. The curves in the figure illustrate the distribution of the 
sizes of the lymph nodes harvested with each of the three methods. Nodes harvested with 
WME and AC are represented by the light grey (AC) and the black graph (WME) and show 
a much more similar distribution in sizes than the MD group. 
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Figure 4.10 Lymph node size according 
to preparation:  
WME resulted in the harvest of the smallest 
nodes with a mean size of 2.25mm; the 
nodes found with AC were only slightly 
larger (2.27mm). Lymph nodes found by MD 
were significantly larger with a mean size of 
3.36mm (p< 0.01).  
 
Figure 4.11: The proportion of small 
nodes found according to preparation:  
The proportion of nodes found by each 
technique, including the nodes harvested 
with a diameter smaller than 2mm (dark grey 
boxes). WME and AC led to the harvest of a 
severely greater proportion of small nodes 

























Figure 4.12 Lymph node size according 
to preparation:  
Kernel density estimation (KDE) was used 
to depict the distribution of the sizes of the 

















4.3.2 Lymph Node Morphometry according to Treatment 
To address the impact of preoperative RCT on lymph node morphology, the morphometric 
descriptors as well as the numbers of lymph nodes per case were considered in relation to 
the clinical treatment (hypothesis 2): 
Preoperative RCT has been reported to be responsible for the shrinkage of lymph nodes in 
CRC specimens (Sprenger et al. 2010), a finding that was confirmed in this study: A 
significant difference in size was observed after comparing the mean lymph node size in 
pretreated specimens (n=5,356; mean size 2.42mm ±1.5) to the mean lymph node size 
after primary surgery (n= 3,167; mean size 3.00mm ±2.1, p<0.001) (Figure 4.14). 
Neoadjuvant RCT causing the shrinkage of lymph nodes was also confirmed after 
subdividing the groups according to preparation and treatment: In the AC group, the mean 
lymph node size was 2.4mm after primary surgery and 2.2mm after neoadjuvant treatment, 
differences in size that are statistically significant (p<0.001). The mean lymph node size in 


























4.3.3 Morphometry of Lymph Node Metastases 
To test if small lymph nodes may be tumor-infiltrated, the status of lymph nodes (unaffected 
or infiltrated) was placed in the context of lymph node size: 
530 of the 8,523 nodes examined in this study were affected by metastases (6.22%). 
Positive lymph nodes were found to be distinctly larger. Lymph node metastases showed a 
Figure 4.14 Lymph node size 
according to treatment:  
Nodes harvested in patients treated 
with preoperative RCT were found to 
be significantly smaller than nodes 
found in patients treated with primary 
surgery (2.42 vs 3.00, p< 0.001).  
 
Figure 4.13 Lymph node size 
according to treatment and 
preparation:  
The AC and MD group were 
subdivided according to treatment and 
lymph nodes in patients treated with 
preoperative RCT were found to be 
significantly smaller than nodes found 
in primarily operated patients in both 
the AC and the MD groups (p< 0.001). 
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Figure 4.15 Lymph node size according 
to nodal status:  
Infiltrated nodes were found to be distinctly 
larger than negative nodes (4.74mm vs 
2.49mm). 
mean diameter of 4.74mm (±2.9), whereas negative nodes showed a mean diameter of 
2.49mm (±1.6) (Figure 4.15). Small nodes can be affected as well, and a distinction is 
made between macro- and micrometastases. Micrometastases are infiltrated lymph nodes 
smaller than 2mm in greatest diameter (Sirop et al. 2011). 52 of the positive nodes 
assessed in this study can be classified as micrometastases. In the WME group, 4 of the 
35 metastases found were micrometastases (11.4%). In the AC group, 257 lymph nodes 
were found prior to acetone compression and 35 showed metastatic involvement, 6 (17%) 
of which were micrometastases. 3,625 nodes were harvested after acetone compression, 
and 100 of these nodes were metastases, 18 of which were smaller than 2mm (18%). 
Using MD, 24 lymph node metastases (6.4%) smaller than 2mm were found. With the use 
of AC, the greatest amount of micrometastases was found (18% vs 11.4% in the WME 
group and 6.4% in the MD group). A larger amount of micrometastases were found in 
patients treated neoadjuvantly as compared to primarily operated patients. Of the 52 
micrometastases examined, 31 (59.6%) were found in patients treated with preoperative 
RCT, the remaining 21 (40.4%) were found in patients treated with primary surgery. In 6 
cases of the AC group, all metastases found were smaller than 2mm and they were all 
harvested in patients treated with preoperative RCT. In 2 of these 6 cases, the nodes were 
found prior to compression, in the remaining 4 cases the nodes were found after acetone 











4.4 Nodal Stage according to Preparation 
To investigate if AC and WME affect the pathological lymph node staging, the tumor stages 
were considered in relation to the employed retrieval method (hypothesis 3): 
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Figure 4.16 The nodal stage of 
the node-positive cases 
according to preparation:  
A distinctly greater proportion of 
cases with only one lymph node 
metastasis (pN1a) was found in 
the WME and AC group compared 
to the MD group. In the MD group, 
the majority of cases presented 
with 7 or more positive nodes 
(pN2b, 40.7%).  
 




















The pathological nodal status according to preparation was evaluated, and a distinct 
distribution of the different nodal stages among the three groups was noted (Figure 4.16). 
In the WME and the AC group, the majority of cases contained only one lymph node 
metastasis and was classified as pN1a (50% in the WME group and 55.8% in the AC 
group), whereas in the MD group, only a small fraction of cases were classified as pN1a 
(14.8%) or pN1b (24.1%). With the use of MD, 20.4% of cases were classified as pN2a and 
the majority of cases (40.7%) was classified as pN2b (more than 7 lymph node 
metastases). In the WME group, there was an equal number of cases classified as pN1b or 
pN2a (21.4%), and only 7.1% of the cases were classified as pN2b. In the AC group, 
20.9% of the cases were classified as pN1b, 7% as pN2a and 16.3% of the cases were 
classified as pN2b. Additionally, the nodal status of the specimens was also evaluated 
according to treatment. It was noted that there was a distinct distribution of pN1a cases 
between the RCT and the surgical group since a larger number of patients treated with 
preoperative RCT were classified as pN1a (37.5%) than patients treated with primary 
surgery (30.2%). The fraction of patients classified as pN1b or pN2a is comparable 
between the RCT and the surgical group (25% vs 20.9% and 12.5% vs 16.3%), but a 
distinctly greater number of patients in the surgical group presented with 7 or more 
metastases (32.6%) than patients in the RCT group (25%) (Figure 4.17). In Figure 4.18, 
nodal stage of patients in the AC group according to treatment is depicted. A severely 
larger proportion of patients treated with preoperative RCT was classified as pN1a than 
patients who were primarily operated (65.2% vs 45%). In the RCT group, only 13% of 
patients were classified as pN2b, whereas in the surgical group, 15% were classified as 





























Figure 4.17 The nodal stage of 
the node-positive cases 
according to treatment:  
A greater proportion of cases with 
only one positive lymph node 
(pN1a) was found in patients 
treated with RCT compared to 
primarily operated patients (37.5% 
vs 30.2%). 
 
Figure 4.18 The nodal stage in 
the AC group according to 
treatment:  
A greater proportion of pN1a cases 
was found in patients treated with 
preoperative RCT than in patients 
who were primarily operated 

































Patients in the MD group were also subdivided according to year of treatment.  89 patients 
in the MD group were treated between 2005 and 2009. 37 of these patients (41.6%) were 
node-positive and 3 (8%) were classified as pN1a. 42 patients in the MD group were 
treated between 2010 and 2012. 17 of these patients (40.5%) were node-positive and 5 
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(29.4%) were classified as pN1a. A variance in nodal stage was noted between the older 
cases and the patients treated more recently as a greater proportion of patients treated 
more recently were classified as pN1a (29.4% vs 8%). A similar amount of patients was 
treated with preoperative RCT in both groups (51.7% vs 47.8%) (Table 4.2). 
 
 
 2005 to 2009 2010 to 2012 
Number of cases 89 42 
Neoadjuvant treatment 46 (51.7%) 22 (47.8%) 
Node-positive 37 (41.6%) 17 (40.5%) 
pN1a 3 (8%) 5 (29.4%) 
 
Table 4.2 Patients in the MD Group Subdivided by Year of Treatment 
 
4.5 Lymph Node Size and Tumor Regression Grading (TRG) according to Preparation 
To test if lymph node sizes and lymph node yield are interrelated to the response to 
preoperative RCT, the parameters were considered in relation to the regression grade 
(hypothesis 2):  
The tumor regression grading (TRG) of the specimens was microscopically assessed and 
classified according to Dworak (Dworak et al. 1997). TRG is regarded as patient response 
to preoperative RCT, ranging from TRG 0 (a specimen showing no regression) to TRG 4 
(no viable tumor cells left, total regression). 73 of the patients in this study showed tumor 
regression 0 to 2, and 46 patients showed tumor regression 3 or 4. A greater amount of 
tumors showing TRG 0 to 2 were node-positive (25, 34.1%) than tumors with TRG 3 or 4 
(9, 19.5%) (Table 4.3). These two groups (TRG 0 to 2 and TRG 3 or 4) were further 
subdivided according to the technique used for lymph node preparation. TRG 0 to 2 was 
observed in 48 cases in the AC group and in 25 cases in the MD group. TRG 3 or 4 was 
observed in 29 cases in the AC group and in 17 cases in the MD group. In the MD group, a 
significantly larger number of cases showing TRG 0 to 2 were node-positive than cases 
showing TRG 3 or 4 (52% vs 11%). In the AC group, a similar amount of cases showing 
TRG 0 to 2 or TRG 3 or 4 were node-positive (25% vs 24%).The lymph nodes in the MD 
group showing TRG 0 to 2 or TRG 3 or 4 were larger than the nodes with TRG 0 to 2 or 
TRG 3 or 4 in the AC group (the mean size of 3.03mm and 2.73mm vs 2.24mm and 
2.05mm).  
Additionally, a relation between TRG and the presence of micrometastases was noted. In 
patients with a higher grade of tumor regression (TRG 3 or 4), 9 of 42 metastases could be 
classified as micrometastases (21.4%), whereas in patients with TRG 0 to 2 only 10 of 142 
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(7%) metastases were smaller than 2mm. It was also noted that more micrometastases 
found using AC showed tumor regression 3 or 4 than micrometastases found through MD 








4.6 The Efficiency of Acetone Compression 
Several technical parameters were recorded to investigate the efficiency and reproducibility 
of AC (hypothesis 3): 
AC obtains sufficient lymph node harvest by combining elution in acetone with the manual 
compression of mesorectal fatty tissue. Manual compression results in the draining of most 
of the acetone and fat and thus a reduction of the initial weight. Prior to AC, the mean 
weight of the fatty tissue was 273g (±151g) and 24.6g (±19.4g) after AC, resulting in a 
weight reduction of the remaining tissue of 91% (±3.5%). As mentioned earlier, the greatest 
morphometric descriptors were comparable between the lymph nodes harvested with WME 
and AC (roundness, aspect ratio, mean area and the mean perimeter) (Table 4.5). The 
integrity of all nodes was assessed, and 87% (±7%) of the nodes found with WME and 
75% (±15%) of the nodes found with MD were untruncated. In the AC group, 64% (±25%) 
 Tumor regression 0 to 2 Tumor regression 3 or 4 
Cases 73 46 
Nodal-positive cases 25 (34.1%) 9 (19.5%) 
pN+ (mic) 1 (4%) 3 (33.3%) 
pN1a 12 (48%) 4 (44.4%) 
Positive nodes (all) 142 (5.68/case) 42 (4.66/case) 
Micrometastases 10 (7%) 9 (21.4%) 
Mean size positive nodes 4.7mm (±2.7) 4.64mm (±3.07) 
 Tumor regression 0 to 2 Tumor regression 3 or 4 
 MD AC MD AC 
Cases 25 48 17 29 
Nodal-positive cases 13 (52%) 12 (25%) 2 (11%) 7 (24%) 
pN+ (mic) 0 1 (8.3%) 0 3 (42.9%) 
pN1a 3 (23%) 9 (75%) 0 4 (57%) 
Positive nodes  102 40 25 17 
Micrometastases  5 (4.9%) 5 (12.5%) 3 (12%) 6 (35.3%) 
Table 4.3: Nodal Status and the Presence of mi in Patients who Underwent Preoperative 
RCT Subdivided by TRG 
 
Table 4.4: Nodal Status and the Presence of mi in Patients who Underwent Preoperative 
RCT Subdivided by TRG and Technique for Lymph Node Harvest 
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of the nodes harvested were untruncated. The efficiency of AC is based on the decisive 
weight reduction of the fatty tissue and, in this study, resulted in a workload of 25 (±14) 






Roundness 0.68 0.69 
Aspect ratio 1.58 1.58 




                                   

















Lymph nodes and their swelling in inflammatory and neoplastic diseases were observed by 
ancient Greek and Roman physicians during the beginnings of humoral pathology 
(Crivellato et al. 2007). With the advent of cellular pathology, the mechanisms of metastatic 
spread were revealed and the prognostic value of lymph nodes was recognized. Ever 
since, the best mode of lymph node retrieval and the most significant way to interpret them 
have been a matter of debate. With the introduction of highly efficient neoadjuvant 
irradiation combined with chemotherapy, this matter is as important as ever. Several 
different approaches to lymph node retrieval are employed by pathologists and have been 
described in this study, in which a more recent method for comprehensive lymph node 
retrieval from fatty tissue, the so-called acetone compression (AC), was analyzed and 
compared with two other methods: whole mesorectal embedding (WME) and manual 
dissectioning (MD). The findings of this study have made it possible to describe the 
efficiency of the different methods as well as the impact of preoperative radiation on lymph 
node morphometry. 
5.2 Lymph Node Yield in CRC Specimens 
5.2.1 The Impact of Lymph Node Yield in CRC Specimens 
The histological lymph node assessment of CRC resection specimens is of crucial 
importance for a number of reasons. Besides enabling physicians to determine the tumor 
stage, the nodal assessment also has an impact on their ability to specify the patient's 
prognosis and determine the course of treatment. The presence of a single lymph node 
metastasis causes a shift in the tumor stage from stage II to stage IIIA (Wittekind and 
Meyer 2010) and consequently, the 5-year disease-specific survival rate drops from 94.1 to 
79.1 in colon cancer patients and from 88.3 to 69.1 in rectal cancer patients (Kanemitsu et 
al. 2012). The nodal status is one of the most important prognostic factors in CRC patients, 
and decisions on therapy rely on it. In colon cancer patients, the administration of adjuvant 
chemotherapy is only indicated in node-positive stage III patients (Schmiegel et al. 2008). 
Further therapeutic decisions, such as the resection of liver metastases in CRC patients, 
are also based on the presence of positive lymph nodes (Fong et al. 1999).  
5.2.2 The 12-lymph-node-minimum 
To ensure adequate nodal assessment, a sufficient number of lymph nodes must be 
harvested and examined, a factor which has been recognized by the UICC. The harvest of 
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12 to15 negative lymph nodes has been found to accurately reflect nodal negativity, 
resulting in the UICC’s decision to recommend the harvest of a minimum of 12 nodes per 
patient (Compton et al. 2000). This recommendation is based on the findings of two 
studies. Scott et al. compared the lymph node yield obtained through manual dissectioning 
and additional fat clearance methods in 41 rectum and 62 colon specimens and showed 
that by administering additional fat clearance methods, 12.4 additional nodes per specimen 
could be harvested (Scott et al. 1989). Ratto et al. conducted a study that involved the 
investigation of lymph node yield and the survival rates of 801 CRC patients and were able 
to demonstrate an association between node-positivity and negative outcome, higher rates 
of local recurrence and distant metastasis (Ratto et al. 1999).  
While the UICC does not encourage the retrieval of additional nodes, several lines of 
evidence indicate that a comprehensive lymph node investigation may yield further relevant 
information. Besides allowing accurate nodal assessment, harvesting a high number of 
lymph nodes has also been reported to improve patient survival. Tepper et al. found an 
association between longer relapse time and better chances of survival in node-negative 
rectal cancer patients when a large number of nodes were harvested (Tepper et al. 2001). 
Kotake et al. showed an association between better chances of survival and a greater 
lymph node count in both stage II and stage III CRC patients (Kotake et al. 2012).  
5.2.3 Techniques for Lymph Node Retrieval 
In view of the importance of sufficient lymph node retrieval, a number of techniques for the 
improved histopathological workup of CRC resection specimens have been introduced over 
the years: fat clearance techniques such as the application of Carnoy’s solution, methylene 
blue injection or whole mesorectal embedding. In the present study, lymph node yield 
obtained through conventional manual dissectioning, whole mesorectal embedding and 
acetone compression was assessed and compared. WME is the most extensive of all three 
methods and since- other than MD or AC- it is a technique that does not involve use of 
solvents or mechanical compression, it can be regarded as a reference standard. WME 
proved to be the most comprehensive technique as it resulted in the harvest of 34 (±17) 
nodes per case. AC also presented as a method of high accuracy with a mean number of 
28 (±13) nodes per case, whereas MD led to the harvest of a significantly smaller number 
of nodes (22±10). Those cases that had at least 12 nodes examined were evaluated and 
WME was successful in meeting the UICC benchmark in all 51 cases (100%), and AC in 
93.5% of the cases. In the MD group, only 90% of all cases had 12 or more nodes 
examined. The failure of MD to guarantee thorough lymph node harvest is even more 
noteworthy in view of the fact that the numbers of lymph nodes found manually in this study 
were comparatively high: In a study involving 221 rectal cancer patients, Cawthorn et al. 
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found a mean number of 10.5 nodes per case through MD (Cawthorn et al. 1986). Märkl et 
al. compared conventional MD and methylene blue injection in 669 CRC patients and found 
a mean number of 13 nodes with MD (Märkl et al. 2013b), and Jass et al. harvested a 
mean number of 18.7 nodes per case with MD after comparing the thoroughness of fat 
clearance and MD in 20 rectal specimens (Jass et al. 1986).  
5.2.4 Lymph Node Size 
Whereas most studies involving lymph node yield in CRC based their decision to count 
nodes solely on the size of the node in question (Märkl et al. 2007, Brown et al. 2004), 
nodes in this study were identified according to four histological criteria (the shape of the 
node, histological structure, the presence of a capsule and the presence of blood vessels). 
Of these four criteria, at least two had to be present, ensuring a distinction between 
lymphoid inflammatory infiltrate and actual lymph nodes. Aside from a distinction in the 
numbers of nodes found with each technique, there was also a significant variation of the 
mean lymph node size among the three groups as the lymph nodes found with WME and 
AC were significantly smaller than the nodes harvested manually (the mean size in mm in 
the WME and AC groups: 2.25 and 2.27 vs 3.36 in the MD group). WME and AC also led to 
the harvest of the greatest proportion of very small nodes (with mean sizes below 2mm). 
920 (52%) of the nodes found with WME and 2,099 (58%) of the nodes found with AC were 
smaller than 2mm. In the MD group, only 791 (25%) of the harvested nodes were smaller 
than 2mm. If a similar size distribution can be assumed to occur in all groups, MD seems to 
miss every second small node.  
5.2.5 Infiltrated Nodes 
Infiltrated lymph nodes have been reported to be larger than negative nodes (Cserni 2002), 
a finding that was confirmed in this study. Positive nodes were significantly larger than 
negative nodes in all cases (4.74mm vs 2.49mm, p<0.001). It is interesting to note that the 
infiltrated nodes show comparable sizes between the three retrieval techniques (means, 
WME=4.77mm, AC= 4.69mm and MD=4.76mm). Nevertheless, a considerable amount of 
infiltrated nodes in this study were found to be smaller than 2mm (52 of 530 positive nodes) 
and thus can be classified as micrometastases (mi) (Sirop et al. 2011). Compared to WME 
and MD, AC led to the harvest of the greatest number of mi (18% vs 11.4% and 6.4%). The 
presence of mi was recognized as early as 1999, not only for CRC but for other forms of 
cancer as well (Hermanek et al. 1999). However, their prognostic significance is still 
uncertain, especially in stage II CRC patients. Liefers et al. found stage II CRC with mi to 
have a lower five-year survival rate than stage II patients without mi and since there are still 
as many as 20% of stage II CRC patients that die of recurrent disease (Liefers et al. 1998), 
it has been suggested that an oversight of mi during histological assessment might be the 
 55 
reason for this poor outcome (Märkl et al. 2013a). However, there are also experts 
questioning the prognostic significance of mi, especially in irradiated rectal cancer patients. 
Most of the mi in this study was found in patients treated with preoperative RCT (59.6% vs 
40.4%), and the presence of mi in irradiated specimens was associated with better tumor 
regression. This finding confirms the assumption that mi might be regarded as a sign of 
treatment response to RCT (Sprenger et al. 2013b). The role of mi in CRC, both in 
pretreated and nonirradiated patients, remains controversial and should be further 
examined in future studies.  
5.2.6 Lymph Nodes and other Parameters 
As shown by the results of this study, lymph node yield obtained through different 
pathologic workup methods varies significantly, and WME and AC have proven to be much 
more thorough in harvesting lymph nodes than MD. Although increased survival rates due 
to the harvest of a larger number of nodes per patient has been demonstrated in a number 
of studies, the reason for this phenomenon is still unknown. Some believe certain patient- 
or tumor-related characteristics to be responsible for the variation in lymph node yield 
among patients. Chou et al. examined clinical and pathologic factors in 153,483 patients 
with CRC stages I to III and observed that "for every 10-year incremental increase in age, 
there was an average reduction of 9% in lymph node harvest", resulting in an average of 
9.3 lymph nodes found in rectal cancer patients older than 70 years (Chou et al. 2010, p. 
2565). Kanemitsu et al. evaluated the lymph node yield in 4,538 colon and rectal cancer 
patients and found an association between a higher lymph node number for both younger 
age (<60 years) and the female sex in rectal cancer patients (Kanemitsu et al. 2012). The 
factors of age, gender and tumor-stage were related to the number of lymph nodes 
investigated in this study. None of the reported associations were reflected by the 320 
cases investigated, i.e. the total number of nodes and the number of positive nodes were 
independent of age and gender, and no relation to tumor stage was found. However, in the 
AC cases, a correlation between the weight of the fatty tissue prior to compression and the 
total number of lymph nodes harvested was found (Pearson's correlation coefficient was 
r=0.417). It has also been suggested that a more favorable tumor-host interaction results in 
a higher lymph node count since more and larger nodes can be regarded as "the 
expression of an enhanced immunological defense" of the body towards the tumor (Märkl 
et al. 2012, p. 1420), and an increase of nodes in size facilitates the harvest. Other factors 
considered to be associated with a higher lymph node count are the presence of the MSI 
phenotype (Eveno et al. 2010), the size and location of the tumor or more advanced pT 
stages (Shia et al. 2012).  
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5.2.7 Achieving the 12-lymph-node-minimum 
Since a sufficient lymph node yield is necessary for accurate staging and thus treatment 
decisions, many think the number of harvested nodes might be a surrogate parameter for 
the hospital's quality of medical care (Denham et al. 2012). Although this has not been 
proven with certainty so far, the fact is that there are still a large number of hospitals that do 
not meet the benchmark of harvesting at least 12 nodes: When comparing lymph node 
yield in CRC patients, Lagoudianakis et al. found that of the 454 CRC patients, only 41.6% 
had 12 or more nodes examined (Lagoudianakis et al. 2011). Baxter et al. found that only 
37% of the CRC patients had at least 12 nodes examined (Baxter et al. 2005), and even 
though colon cancer patients have been reported to have more lymph nodes retrieved than 
rectal cancer patients (Chou et al. 2010), Bilimoria et al. still found that as many as 60% of 
the hospitals across the U.S. failed to meet the 12-node-minimum in colon cancer patients 
(Bilimoria et al. 2008). To a certain degree, variance in lymph node yield within one 
institution seems to be a common phenomenon. Parkash et al. compared the lymph node 
yield of pathologists from two affiliated institutions and found that, in terms of counting 
lymph nodes on glass slides, "there was no slide on which all pathologists agreed on all 
occasions" (Parkash et al. 2010, p. 42). The discrepancy in the lymph node yield among 
pathologists working at the same institution was observed in this study as well. The manual 
lymph node harvests of four pathologists were compared, and a significant difference in the 
number of harvested nodes was found for one pathologist, while the other three yielded 
comparable results. In view of the fact that the numbers of manually retrieved nodes in this 
study were comparably high, it appears likely that the variance of lymph node yield among 
different pathologists might be even higher within other institutions. Even though such 
variances in the lymph node yield within one institution do not necessarily imply poor 
quality in medical care, they could be overcome through the introduction of guidelines and 
more standardized procedures in daily pathological workup.   
5.2.8 The Concept of Stage Migration 
One of the most frequently-discussed reasons for the association between harvesting more 
lymph nodes and better chances of survival is the concept of stage migration, also known 
as the 'Will Rogers Phenomenon' (Märkl et al. 2013b). Stage migration implies "spurious 
understaging because too few nodes are removed/examined and possibly small lymph 
nodes with metastases missed" (Parkash et al. 2010, p. 47). Some experts think this is the 
reason for the higher lymph node count causing improved survival rates (Scott et al. 1989). 
However, the data from this study refute this concept: WME and AC resulted in a 
significantly higher lymph node yield than MD but they also contained a large number of 
cases with only one lymph node metastasis present (pN1a, 50% and 55.8%). In the MD 
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group, on the other hand, only 14.8% of the cases were classified as pN1a, whereas the 
majority of the cases were classified as pN2b (40.7%). Additionally, based on the present 
results, no correlation between the total number of nodes per case and the number of 
positive lymph nodes was found. There was no increase in the number of positive lymph 
nodes noted when the overall number of lymph nodes was high. If stage migration were in 
fact the reason for more lymph nodes causing better chances of survival, a higher rate of 
nodal-positive cases would be expected. Neither is this the case in our study nor in other 
studies (Märkl et al. 2013a, for example), in which it was demonstrated that advanced 
lymph node retrieval techniques or the ultrastaging of lymph nodes does not increase the 
rate of nodal-positive cases. Hogan and Winter suggest the introduction of a 'nodal 
positivity constant' since they observed that the nodal positivity rate in colon and rectal 
cancer patients combined has remained mostly steady over the past years (40% in 1988-
1990, 42% in 2006-2008) (Hogan and Winter 2012) and Parsons et al. showed that 
although lymph node yield in colon cancer patients has been increasing over the years, the 
rate of nodal-positivity has not (Parsons et al. 2011). In view of the anatomic differences 
and the fact that colonic cancer is not treated with neoadjuvant RCT, lymph node yield in 
colon and rectal cancer patients is only comparable to a certain degree. However, the 
observation made by Parsons et al. further underlines the assumption that a greater lymph 
node yield does not necessarily result in the harvest of more positive nodes.  
All in all, the impact of medical care, patient- and tumor-related factors as well as the 
quality of the histopathologic assessment of the lymph node yield and the chances of 
survival represent a multifaceted process involving a number of factors to varying degrees. 
As demonstrated by results of this study, the UICC's recommendation of harvesting at least 
12 nodes per patient is feasible with a technique that allows comprehensive lymph node 
yield such as acetone compression. Even though the exact reasons are still unknown, it 
has been shown repeatedly that CRC patients exhibit increased survival rates when a 
greater number of lymph nodes are detected and when all departments involved (oncology, 
surgery and pathology) cooperate efficiently. It seems reasonable to demand that in future 
all CRC patients should have at least 12 nodes harvested and examined. 
5.3 The Impact of Preoperative Radiation on Lymph Node Yield and Morphometry 
The administration of radiation and chemotherapy prior to surgery has become standard in 
the treatment of locally advanced rectal carcinoma in Germany based on the findings of the 
CAO/ARO/AIO-94 study and follow-up studies. The studies demonstrated the clinical 
advantages of preoperative RCT such as the improvement of sphincter-preservation or the 
lower rates of local recurrence (Sauer et al. 2004). Even though long-course radiotherapy 
has proven to be very effective by causing both nodal and tumor down-staging (Francois et 
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al. 1999), it also impedes the nodal assessment of CRC specimens since it is known to 
cause "lymphocyte depletion" as well as "atrophy and fibrosis of the stroma" (Baxter et al. 
2005, p. 429). A number of studies on the impact of preoperative RCT on lymph node 
retrieval have been conducted over the years and it seems as if the majority of them 
indicate that RCT (both long-term as well as short-term radiotherapy) impairs the number 
and size of lymph nodes harvested from irradiated specimens. The results of this study 
show that with regard to lymph node size, there was a significant difference between the 
irradiated and the non-irradiated groups. In all cases, patients who received preoperative 
RCT had lymph nodes with a mean size of 2.42mm, whereas the lymph nodes of patients 
treated solely with surgery had a mean size of 3.00mm (p<0.001). After subdividing the 
groups according to the methods used for retrieval, both the AC group (mean lymph node 
size 2.4mm and 2.2mm) and the MD group (mean lymph node size 3.6mm and 3.0mm) 
showed smaller lymph nodes after treatment with preoperative RCT (p<0.001). In the WME 
group, all patients were treated with RCT, and the mean sizes of the nodes of the WME 
group and the irradiated AC group were comparable (2.25 vs 2.2, p= 0.108).  
With regard to the number of harvested lymph nodes after pretreatment, the present results 
demonstrate that preoperative radiotherapy does affect the number of retrieved lymph 
nodes if the nodes are harvested through manual dissectioning. The mean number of 
harvested nodes decreased from 25 to 19 nodes per case in nonirradiated and irradiated 
patients of the MD group (p= 0.0032). In the AC group, on the other hand, the mean 
number of nodes harvested per case was not significantly affected by radiation compared 
to patients who were primarily operated (30 vs 27, p=0.13). Thus, factors other than 
pretreatment seem to influence the number of retrieved nodes within the AC group. This is 
not the case in the MD group. Here, pretreatment does cause a significant reduction of 
retrieved nodes and most cases not reaching the UICC-threshold are pretreated 
(Pretreated: 10/68= 14.7%; primarily operated: 3/63= 4.8%). In part, this distribution might 
be explained by the size reduction of the lymph nodes caused by preoperative radiation. 
Thus, it seems a more comprehensive technique might be better to work-up pretreated 
rectal cancer specimens.  
Treatment response to preoperative radiation is microscopically evaluated based on the 
extent of tumor regression found in the resection specimen. In addition to reflecting 
treatment response, recent data indicate tumor regression grading (TRG) to be a 
prognostic factor as well. Rödel et al. evaluated the impact of TRG on survival in the 
context of the CAO/ARO/AIO-94 trial on rectal cancer and found an association between 
poor tumor regression and a higher risk of lymph node involvement and poorer chances of 
survival (Rödel et al. 2005). The association between poor tumor regression and lymph 
node involvement has been confirmed in the findings of this study as well since more nodal 
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positive cases (34.1%) showed poor regression (TRG 0 to 2) than TRG 3 or 4 (19.5%). The 
effect of RCT is reflected by a number of findings in the present study.  After comparing the 
pathological nodal status according to treatment, a greater proportion of cases with only 
one lymph node metastasis (pN1a) was found in pretreated patients compared to patients 
who were primarily operated (37.5% vs 30.2%), which might be due to the downstaging 
effect of the pretreatment. 52 of the lymph node metastases found in this study can be 
classified as micrometastases and the majority of these nodes were found in patients 
treated with preoperative RCT (59.6% vs 40.4%). Additionally, an association between 
micrometastases and tumor regression was observed since patients with higher grades of 
tumor regression (TRG 3 or 4) showed more micrometastases than patients with poor 
tumor regression (TRG 0 to 2): 21.4% vs 7%. This association between tumor regression 
and the presence of micrometastases might support the idea that micrometastases be 
thought of as "regressive micrometastases" (Sprenger et al. 2013b, p.6) and thus mirrors a 
patient’s response to treatment.  
Despite several studies demonstrating the effect of RCT on lymph node yield, there are no 
recommendations regarding standardized, efficient lymph node yield in irradiated 
specimens (Sprenger et al. 2010).  Baxter et al. found an average of 3 nodes fewer in 
irradiated specimens, and in 16% of the patients treated with RCT, no nodes were 
harvested at all (Baxter et al. 2005). Rullier et al. found preoperative RCT to decrease the 
number of lymph nodes harvested by as much as 24% (13 vs 17) and the number of lymph 
node metastases by 48% (1.2% vs 2.3%) (Rullier et al. 2008). Govindarajan et al. even 
question the entire concept of harvesting a minimum of 12 lymph nodes per patient and 
claim that it is not feasible in patients who underwent RCT, as they found an average of 
five nodes fewer harvested in irradiated than in non-irradiated patients (10.8 vs 15.5), and 
63% of the patients in the RCT group had fewer than 12 nodes examined (Govindarajan et 
al. 2011). According to Sprenger et al. the "radiation-related reduction of lymph node size 
might be the main reason for a reputedly reduction of lymph node numbers in irradiated 
specimens worked up with conventional (manual) retrieval because of the apparent 
difficulty to detect lymph nodes smaller than 0.2cm" (Sprenger et al. 2010, p.101), an 
argument that is supported by the present results, which demonstrate both fewer small 
nodes (<0.2cm) detected by MD and a significant decrease in lymph node size after 
radiation. All in all, the data seem to indicate that MD finds fewer nodes after pretreatment 
because the nodes shrink and are less likely to be found manually. Thus, MD does not 
seem to be a reliable method for lymph node harvesting, especially in patients treated with 
preoperative RCT. The aforementioned studies all agree on RCT causing a decrease in 
lymph node yield, and they all used MD to find lymph nodes, except Sprenger et al., who 
used WME and demonstrated the harvest of smaller but not necessarily fewer lymph nodes 
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after RCT. However, they also acknowledge that WME is too elaborate a method for 
routine processing (Sprenger et al. 2010). The results of the present study are consistent 
with the findings of a study conducted by Gehoff et al., which showed that conventional MD 
results in a smaller lymph node yield in irradiated specimens than AC does, even if fat 
clearance methods are applied in addition to MD (Gehoff et al. 2012a). According to these 
results and the findings of the present study, AC seems to be a valid approach to ensure 
sufficient lymph node yield in CRC, both in irradiated and non-irradiated specimens, and 
the proposal of Govindarajan et al. to question the feasibility of the 12 lymph-node 
threshold in irradiated specimens (Govindarajan et al. 2011) no longer applies.  
5.4 The Efficiency of Acetone Compression 
The importance of adequate lymph node assessment in CRC patients has been proven 
sufficiently and optimizing lymph node harvesting by introducing a variety of new methods 
has been the aim of several studies over the years. MD was the standard in harvesting 
lymph nodes for a long time, but it has become increasingly obvious that this method has a 
number of shortcomings. MD is a method which greatly depends on the skill of the 
pathologist responsible. As the results of the present study show, its efficiency can vary 
significantly among different pathologists within one institution. Literature on lymph node 
numbers indicates an even higher variance between different institutions. MD resulted in 
the harvest of fewer lymph nodes than WME and AC (22 vs 28 and 34), and since MD 
failed to enable the harvest of small nodes (the mean size of nodes found with MD in this 
study was 3.36mm), it is not surprising that the 12-lymph node minimum recommended by 
the UICC could not be met in 10% of the cases examined manually. Additionally, MD 
resulted in the harvest of a significantly smaller number of nodes in patients treated with 
preoperative RCT (the mean number of nodes found in patients treated with primary 
surgery or RCT: 25 vs 19, p=0.0032). 
These limitations have been noted in other studies as well and led to the introduction of 
more advanced pathological workup techniques, including fat clearance methods, 
methylene blue staining or acetone compression. Fat clearance is based on the elution of 
fatty tissue with different chemicals (e.g. alcohol and xylene), depending on the type of 
clearing method used. The resulting decolourisation of the tissue facilitates localization of 
the lymph nodes and has proven to provide a greater lymph node yield than MD in a 
number of studies (Jass et al. 1986, Herrera et al. 1992, Brown et al. 2004). Despite 
resulting in a more efficient lymph node harvest than conventional MD, fat clearance 
methods show a number of limitations as well. Abbassi-Ghadi et al. compared efficiency, 
costs and the time exposure of different workup methods and found fat clearance to be 
rather expensive and time-consuming with a median preparation time of 79 hours (Abbassi-
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Ghadi et al. 2012). Additionally, the solvents used for fat clearance, such as xylene or 
methyl salicylate, are considered to be harmful and require fume hoods as well as special 
rooms to work in. The disposal of the solvents used is also difficult as they cannot be 
simply drained into a sink (Jass et al. 1986). Märkl et al. were able to outline the advantage 
of methylene blue staining over manual dissection as the mean lymph node harvest in their 
study was 86% higher than the harvest of the unstained group (Märkl et al. 2007). Despite 
ensuring an effective lymph node yield, methylene blue injection still remains a rather 
elaborate method as it also requires at least 16 hours of preparation (Basten et al. 2010).  
In comparison to these methods, acetone compression seems to be a much more efficient 
technique for both a quick and sufficient lymph node harvest. By microscopically examining 
and digitalizing 8,523 lymph nodes from 320 rectal cancer specimens harvested with three 
different pathological methods, AC has proven to be almost as thorough in lymph node 
harvest as the more extensive WME method (the mean number of nodes harvested 34 vs 
28), while being significantly more efficient than MD (28 vs 22). Acetone has been used by 
Brown et al. in combination with alcohol and xylene in terms of a fat clearance method 
(Brown et al. 2004) and was established and first introduced as a newly-developed method 
by Basten et al. in 2010 (Basten et al. 2010). AC was performed in this study according to 
this original protocol except for the slight alteration of using acetone at room temperature 
instead of heating it. The temperature was changed because of the findings of a study 
conducted by Gehoff et al., revealing difficulty in cutting the tissue blocks as well as the 
hampered quality of IHC staining when acetone was heated (Gehoff et al. 2012a). The use 
of non-heated acetone has shown presentable results in the present study. A robust 
compression was achieved, causing a weight reduction in the fatty tissue by 91% (±3.5%). 
A mean number of 25 (±14) capsules per case was established, containing a mean number 
of 1.5 (±1.6) nodes per capsule. AC may result in a higher number of tissue blocks than 
other pathological workup methods but processing times are still reasonable. Gehoff et al. 
found AC to be "as effective as the WME method, but the AC method was much faster, 
with the total processing time within the range of conventional pathology workup" (Gehoff et 
al. 2012a, p. 211) and according to Basten et al., if the preparation of the specimen takes 
place in the morning, it can be fully diagnosed the following day. Additionally, AC seems to 
be much more cost-efficient and environmentally-friendly than techniques using solvents 
for fat clearance as the acetone used can be filtered or distilled and reused. It is a very 
feasible method that can be carried out by lab technicians and does not require special 
surgical preparation of the specimen beforehand (Basten et al. 2010). Although we did find 
a greater amount of lymph nodes to be truncated after the harvest with AC as compared to 
WME and MD, the tissue treated with acetone still contained blood vessels, nerve tissue 
and lymph nodes that showed morphometric characteristics comparable to those of the 
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lymph nodes found with the extensive WME method. Lymph nodes have been reported to 
have the tendency to shrink in the course of fixation and processing (Märkl et al. 2012) and 
the fact that the nodes harvested with AC are of a size similar to that of the nodes in the 
WME group (2.27 vs 2.25) also indicates that treatment with acetone does not impair the 
quality of the tissue. In a case report published by Gehoff et al., AC not only resulted in the 
harvest of 21 additional lymph nodes in a rectal cancer resection specimen after MD, it also 
enabled the harvest of one positive node that had not been detected by the previous MD, 
thus greatly changing the diagnosis of the patient’s tumor stage and subsequent course of 
treatment. Gehoff et al. also emphasize that AC allows for the detection of tumor cell 
deposits, small nests or nodules that represent residual lymph nodes and are equally as 
relevant for determining the tumor stage as macro- or micrometastases (Gehoff et al. 
2012b). In addition to this, AC is not only of relevance in the lymph node assessment of 
CRC specimens but can also prove useful for the workup of fatty tissue in other forms of 
cancer such as neuroendocrine tumors (Scheel et al. 2013), thus bearing the potential for 
more widespread use in pathological workup. Consequently, even though WME has proven 
to be the most thorough of all methods, it is too elaborate to be suitable for everyday 
purposes. AC is much more practicable and seems to be an adequate alternative to routine 
histopathological assessment of CRC resection specimens that allows thorough lymph 
node yield even in patients treated with preoperative RCT. 
5.5 Outlook and Limitations 
Despite the extensive assessment of the harvested lymph nodes of 320 rectal cancer 
patients, the present study presents with limitations as well. The study’s design was 
retrospective, which restricts the comparability of the different cases. In addition, there are 
certain disparities regarding the patient cohort:  the cases of the MD group were treated 
between 2005 and 2012, whereas the patients of the AC group were treated between 2009 
and 2012. None of the patients of the MD group were enrolled in a clinical trial, whereas 15 
patients of the AC group and all of the patients of the WME group were enrolled in the 
CAO/ARO/AIO-2004 study, which implies more standardized diagnostic and treatment 
proceedings. With treatment regimens changing and improving over time, the fact that 
some of the cases in the MD group were treated earlier than those in the AC group might 
account for the uneven distribution of pN1a and pN2b case. A shift in the pN-stages was 
seen after subdividing the MD cases by year of treatment: 89 patients in the MD group 
were treated between 2005 and 2009. 3 (8%) of the nodal-positive patients were classified 
pN1a. 42 patients in the MD group were treated between 2010 and 2012 and 5 (29.4%) of 
the nodal-positive patients were classified pN1a. For future evaluations it might be 
interesting to perform a prospective observational study and compare survival data of 
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patients according to preparation, number of nodes harvested and treatment to gain 
information about the impact of a more thorough lymph node harvest through acetone 




In spite of the increasing awareness of this disease and the development of more accurate 
screening methods, colorectal cancer is still the third most common type of cancer in the 
world. Mortality rates remain high and incidence rates keep rising, especially in countries 
with growing adaption to the western-type lifestyle. Of all the aspects regarding this 
disease, the pathological nodal status is of crucial importance as it determines the tumor 
stage, the course of treatment and is still considered to be among the patient’s most 
important prognostic factors. The pathological nodal status can only be adequately 
estimated if a sufficient lymph node harvest has taken place. Over the years, a number of 
advanced methods for lymph node retrieval in CRC specimens have been developed 
(manual dissectioning, fat clearance methods, methylene blue staining, WME or acetone 
compression), each with various levels of efficiency. The optimal number of lymph nodes to 
be harvested is still under debate but the UICC recommends assessing a minimum of 12 
nodes per patient. Administration of preoperative radiochemotherapy has been reported to 
cause lymph node shrinkage and even diminish the amount of nodes present in a 
specimen. 
The present study evaluated the lymph node yield of 320 patients with locally advanced 
rectal carcinoma. The nodes were obtained through three different workup methods: whole 
mesorectal embedding, manual dissectioning and acetone compression. 8,523 lymph 
nodes were microscopically examined, digitalized and subjected to morphometry. The 
slides were stained with hematoxylin and eosin and in questionable cases, IHC staining 
with panCK was supplemented. To ensure differentiation of actual lymph nodes and 
lymphoid infiltrates, two of the following pre-determined criteria had to be recognizable in 
each node: the shape of the node, the presence of a capsule, follicular lymphoid tissue and 
the presence of blood vessels. By manually drawing the nodes during morphometry, 
information about the geometric characteristics were gathered.  
Lymph nodes were found to be larger if infiltrated with malignant cells and smaller after 
preoperative radiation. Preoperative radiochemotherapy was also found to induce tumor 
regression of the primary tumor and of the lymph node metastases and was associated 
with the presence of micrometastases. In terms of the thoroughness of the three methods, 
acetone compression resulted in the harvest of significantly more and smaller lymph nodes 
than manual dissectioning (28 vs 22 nodes per patient and a mean size of 2.27mm vs 
3.36mm), while proving to be almost as thorough as the more extensive and time-
consuming WME method. AC also succeeded in reaching the UICC recommendation of 
harvesting a minimum of 12 nodes per patient to a satisfactory extent (in 93.5% of cases) 
and allowed for the harvest of a sufficient amount of lymph nodes (including very small 
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nodes) both in patients treated with preoperative radiochemotherapy and in patients treated 
with primary surgery (the mean number of 30 nodes per patient in nonirradiated specimens 
and 27 nodes per patient in irradiated specimens). Unlike other pathological methods 
available for lymph node yield, acetone compression is less time-consuming, does not 
require the contact with or disposal of harmful chemicals while obtaining reproducible 
results of a decent quality, suitable even for IHC staining or mutation analysis.  
Despite the knowledge about the importance of adequate nodal assessment and the 
varying efficiency of the different pathologic methods, there is still a lack of guidelines 
regarding the standardization of lymph node harvest in CRC specimens. The results of this 
study suggest introducing acetone compression as a very practicable method suitable for 
adequate lymph node harvest in the daily routine pathological workup of CRC specimens, 
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8.1 Stripcharts for All Cases Subdivided by Treatment and Mode of Preparation 
8.1.1 Stripcharts for AC Group, Patients Treated with Preoperative RCT (n=85) 
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8.1.2 Stripcharts for AC Group, Patients Treated with Primary Surgery (n=53) 
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8.1.3 Stripcharts for MD Group, Patients Treated with Preoperative RCT(n=68) 
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8.1.4 Stripcharts for MD Group, Patients Treated with Primary Surgery (n=63) 
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8.1.5 Stripcharts for WME Group (n=51) 
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